var title_f15_25_15760="Arm position";
var content_f15_25_15760=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Position of the arm for implanon insertion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 456px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_25_15760=[""].join("\n");
var outline_f15_25_15760=null;
var title_f15_25_15761="Posterolateral view right elbow";
var content_f15_25_15761=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Posterolateral view of right elbow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 445px; height: 510px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_25_15761=[""].join("\n");
var outline_f15_25_15761=null;
var title_f15_25_15762="Urine sediment showing a broad cast";
var content_f15_25_15762=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F86555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F86555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urine sediment showing a broad cast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Ringsrud KM, Linne JJ. Urinalysis and Body Fluids: A Colortext and Atlas, Mosby, Amsterdam 1995. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_25_15762=[""].join("\n");
var outline_f15_25_15762=null;
var title_f15_25_15763="Patient information: Preventing type 2 diabetes (The Basics)";
var content_f15_25_15763=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16892\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?40/59/41915\">",
"         Diabetes screening tests",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?11/35/11827\">",
"         Patient information: Diet and health (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/39/20083\">",
"         Patient information: Exercise (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/53/3923\">",
"         Patient information: Health risks of obesity (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/14/227\">",
"         Patient information: Hemoglobin A1C tests (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/46/18146\">",
"         Patient information: Quitting smoking (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/40/22144\">",
"         Patient information: The ABCs of diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/49/16147\">",
"         Patient information: Treatment for type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/44/33475\">",
"         Patient information: Type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/52/31554\">",
"         Patient information: Weight loss treatments (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?5/60/6083\">",
"         Patient information: Diabetes mellitus type 2: Alcohol, exercise, and medical care (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/22/9572\">",
"         Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/37/36436\">",
"         Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/32/31239\">",
"         Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Preventing type 2 diabetes (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/preventing-type-2-diabetes-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H5478444\">",
"      <span class=\"h1\">",
"       Can type 2 diabetes be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes! Studies show that people who are at risk can prevent type 2 diabetes by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Losing weight (if they are overweight)",
"       </li>",
"       <li>",
"        Being active",
"       </li>",
"       <li>",
"        Improving the way they eat",
"       </li>",
"       <li>",
"        Taking certain medicines (most often one called",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?0/22/358?source=see_link\">",
"         metformin",
"        </a>",
"        )",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      There&rsquo;s some evidence that quitting smoking also lowers the risk of developing type 2 diabetes, but scientists need to do more studies to be sure. Even so, there are plenty of good reasons to quit. Quitting smoking lowers your risk of stroke, heart disease, and lots of other problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5478459\">",
"      <span class=\"h1\">",
"       What increases my risk for type 2 diabetes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are a few factors that can increase your risk of diabetes, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Being overweight or obese, especially if you carry your extra weight in your belly (as opposed to in your hips, thighs, and butt) &nbsp;",
"       </li>",
"       <li>",
"        Not doing enough physical activity",
"       </li>",
"       <li>",
"        Smoking",
"       </li>",
"       <li>",
"        Having a family history of diabetes",
"       </li>",
"       <li>",
"        Having diabetes during pregnancy, called &ldquo;gestational diabetes&rdquo; (if you are a woman)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Plus, Asian, Latino, or black people are more likely to get diabetes than white people.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5478474\">",
"      <span class=\"h1\">",
"       Are there tests that can find people who are at risk?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. There are 3 different tests that can help doctors tell whether a person might develop type 2 diabetes. All 3 tests measure blood sugar in different ways. &ldquo;Blood glucose&rdquo; is another name for blood sugar.",
"     </p>",
"     <p>",
"      Even though these tests can help predict diabetes, they are not appropriate for everyone. Your doctor or nurse will decide if one of these tests is right for you. Often, people who get tested are overweight and have one other risk factor for diabetes. Examples of risk factors include having a history of diabetes during pregnancy or a family history of diabetes. &nbsp;",
"     </p>",
"     <p>",
"      If a blood test shows that a person&rsquo;s blood sugar is higher than normal but not high enough to be called diabetes, doctors call it &ldquo;pre-diabetes.&rdquo; People with pre-diabetes are at high risk of developing diabetes. &nbsp;",
"     </p>",
"     <p>",
"      <strong>",
"       Fasting glucose test",
"      </strong>",
"      &ndash; This test measures your blood sugar when you have not had anything to eat or drink (except water) for 8 hours. People with pre-diabetes have a fasting glucose between 100 and 125 (",
"      <a class=\"graphic graphic_table graphicRef71506 \" href=\"UTD.htm?40/59/41915\">",
"       table 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Glucose tolerance test",
"        </strong>",
"        &ndash; For this test you do not eat or drink anything for 8 to 12 hours. But then, as part of the test, you have a sugary drink. Two hours later, a doctor or nurse takes a blood sample to see how high your blood sugar got. People with prediabetes have glucose tolerance results between 140 and 199 (",
"        <a class=\"graphic graphic_table graphicRef71506 \" href=\"UTD.htm?40/59/41915\">",
"         table 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        <strong>",
"         Hemoglobin A1C test (also called HbA1C or A1C)",
"        </strong>",
"        &ndash; For this test it does not matter whether you eat beforehand. It is a blood test that shows what your average blood sugar level has been for the past 2 to 3 months. People with pre-diabetes have A1C levels between 5.7 and 6.4.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5478489\">",
"      <span class=\"h1\">",
"       What should I do if I have pre-diabetes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have pre-diabetes, make lifestyle changes to reduce the chance that you will get full-blown diabetes. Here&rsquo;s what you should do:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Lose weight &ndash;",
"        </strong>",
"        Losing 5 to 10 percent of your body weight can lower your risk a lot. If you weigh 200 pounds, that means you should lose 10 to 20 pounds. If you weigh 150 pounds, that means you should lose 7 to 15 pounds.",
"       </li>",
"       <li>",
"        <strong>",
"         Eat right",
"        </strong>",
"        &ndash; Choose a diet rich in fruits, vegetables, and low-fat dairy products, but low in meats, sweets, and refined grains. Stay away from sweet drinks, like soda and juice. &nbsp;",
"       </li>",
"       <li>",
"        <strong>",
"         Be active for 30 minutes a day",
"        </strong>",
"        &ndash; You don&rsquo;t have to go to the gym or break a sweat to get a benefit. Walking, gardening, and dancing are all activities that can help. &nbsp;",
"       </li>",
"       <li>",
"        <strong>",
"         Quit smoking &ndash;",
"        </strong>",
"        If you smoke, ask your doctor or nurse for advice on how to quit. People are much more likely to succeed if they have help and get medicines to help them quit. &nbsp;",
"        <strong>",
"        </strong>",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5478506\">",
"      <span class=\"h1\">",
"       Take your medicines",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your doctor or nurse prescribed any medicines, take them every day, as directed. That goes for medicines to prevent diabetes, and for ones to lower blood pressure or cholesterol. People with pre-diabetes have a higher-than-average risk of heart attacks, strokes, and other problems, so those medicines are important.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5478598\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/14/227?source=see_link\">",
"       Patient information: Hemoglobin A1C tests (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"       Patient information: Type 2 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/40/22144?source=see_link\">",
"       Patient information: The ABCs of diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/49/16147?source=see_link\">",
"       Patient information: Treatment for type 2 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/52/31554?source=see_link\">",
"       Patient information: Weight loss treatments (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11827?source=see_link\">",
"       Patient information: Diet and health (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=see_link\">",
"       Patient information: Exercise (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=see_link\">",
"       Patient information: Quitting smoking (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/53/3923?source=see_link\">",
"       Patient information: Health risks of obesity (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/32/31239?source=see_link\">",
"       Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"       Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/37/36436?source=see_link\">",
"       Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/60/6083?source=see_link\">",
"       Patient information: Diabetes mellitus type 2: Alcohol, exercise, and medical care (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?15/25/15763?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16892 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-65E6C3AFCD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_25_15763=[""].join("\n");
var outline_f15_25_15763=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5478444\">",
"      Can type 2 diabetes be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5478459\">",
"      What increases my risk for type 2 diabetes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5478474\">",
"      Are there tests that can find people who are at risk?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5478489\">",
"      What should I do if I have pre-diabetes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5478506\">",
"      Take your medicines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5478598\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16892\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/59/41915\">",
"      Diabetes screening tests",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/60/6083?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Alcohol, exercise, and medical care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/37/36436?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11827?source=related_link\">",
"      Patient information: Diet and health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=related_link\">",
"      Patient information: Exercise (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/53/3923?source=related_link\">",
"      Patient information: Health risks of obesity (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/14/227?source=related_link\">",
"      Patient information: Hemoglobin A1C tests (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/40/22144?source=related_link\">",
"      Patient information: The ABCs of diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/49/16147?source=related_link\">",
"      Patient information: Treatment for type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/32/31239?source=related_link\">",
"      Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/52/31554?source=related_link\">",
"      Patient information: Weight loss treatments (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_25_15764="Light microscopy kid LPG";
var content_f15_25_15764=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F65560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F65560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light microscopic findings in lipoprotein glomerulopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Capillary lumina are markedly dilated and contain pale-stained thrombus-like substances (*). (Periodic acid-Schiff stain; original magnification: x200.)",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Saito, T, et al. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis 2006; 47:199. Copyright &copy;2006 Elsevier Science, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_25_15764=[""].join("\n");
var outline_f15_25_15764=null;
var title_f15_25_15765="Sensory nerve conduction study";
var content_f15_25_15765=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F55496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F55496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Sensory nerve conduction study",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 466px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Recording of the sensory action potential is helpful in determining the site of nerve injury particularly in those with lesions resulting in sensory symptoms. This illustration depicts a sensory nerve conduction study of the ulnar nerve. Normal latency is seen with lesions of the central nervous system or those that are proximal to the dorsal root ganglion (arrowhead number 1). A more distal lesion (arrowhead number 2) results in a decreased amplitude but normal conduction velocity. Either a compressive mononeuropathy (arrowhead number 3) or generalized demyelinating peripheral neuropathy results in a decrease in both amplitude and conduction velocity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahram Khoshbin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_25_15765=[""].join("\n");
var outline_f15_25_15765=null;
var title_f15_25_15766="Chapter 13A: Meaning of urine electrolytes";
var content_f15_25_15766=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 13A: Meaning of urine electrolytes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/25/15766/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/25/15766/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/25/15766/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/25/15766/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/25/15766/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/25/15766/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/25/15766/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/25/15766/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2008.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the urinary electrolyte concentrations, osmolality, and pH play an important role in the diagnosis and management of a variety of disorders. This chapter will briefly review the meaning of these parameters and the settings in which they may be helpful (",
"    <a class=\"graphic graphic_table graphicRef63690 \" href=\"UTD.htm?24/42/25259\">",
"     table 1",
"    </a>",
"    ). It is important to emphasize that there are no fixed normal values, since the kidney varies the rate of excretion to match net dietary intake and endogenous production. Thus, interpretation of a given test requires knowledge of the patient's clinical state. As an example, the urinary excretion of 125 meq of Na+ per day may be appropriate for a subject on a regular diet, but represents inappropriate renal Na+ wasting in a patient who is volume-depleted.",
"   </p>",
"   <p>",
"    In addition to their clinical usefulness, these tests are simple to perform and are widely available. In most circumstances, a random urine specimen is sufficient, although a 24-h collection to determine the daily rate of solute excretion is occasionally indicated. When K+ depletion is due to extrarenal losses, for example, the urinary K+ excretion should fall below 25",
"    <span class=\"nowrap\">",
"     meq/day.",
"    </span>",
"    A random measurement, however, may be confusing in some patients. If the urine output is only 500",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    because of associated volume depletion, then the appropriate excretion of only 20 meq of K+ per day will be associated with an apparently high urine K+ concentration of 40",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (20",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    &nbsp;&divide; &nbsp;0.5",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    &nbsp;= &nbsp;40",
"    <span class=\"nowrap\">",
"     meq/L).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SODIUM EXCRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The kidney varies the rate of Na+ excretion to maintain the effective circulating volume, a response that is mediated by a variety of factors including the renin-angiotensin-aldosterone system and perhaps atrial natriuretic peptide and related peptides. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6744?source=see_link\">",
"     \"Chapter 8C: Regulation of renal Na+ excretion\"",
"    </a>",
"    .) As a result, the urine Na+ concentration can be used as an estimate of the patient's volume status. In particular, a urine Na+ concentration below 20",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    is generally indicative of hypovolemia. This finding is especially useful in the differential diagnosis of both",
"    <strong>",
"     hyponatremia",
"    </strong>",
"    and",
"    <strong>",
"     acute renal failure",
"    </strong>",
"    . The two major causes of hyponatremia are effective volume depletion and the syndrome of inappropriate antidiuretic hormone secretion (SIADH). The urine Na+ concentration should be low in the former, but greater than 40",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in the SIADH, which is characterized by water retention but normal Na+ handling (ie, equal to intake). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=see_link\">",
"     \"Evaluation of the patient with hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar considerations apply to acute renal failure which is most often due to volume depletion or acute tubular necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15766/abstract/1\">",
"     1",
"    </a>",
"    ]. The urine Na+ concentration usually exceeds 40",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in the latter, in part because of the associated tubular damage and a consequent inability to maximally reabsorb Na+ [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15766/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Measuring the fractional excretion of Na+ and the urine osmolality also can help to differentiate between these conditions (see below).",
"   </p>",
"   <p>",
"    In normal subjects, urinary Na+ excretion roughly equals average dietary intake. Thus, measurement of urinary Na+ excretion (by obtaining a 24-h collection) can be used to check dietary compliance in patients with essential hypertension. Restriction of Na+ intake is frequently an important component of the therapeutic regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15766/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], and adequate adherence should result in the excretion of less than 100",
"    <span class=\"nowrap\">",
"     meq/day.",
"    </span>",
"   </p>",
"   <p>",
"    The concurrent use of diuretics does not interfere with the utility of this test as long as drug dose and dietary intake are relatively constant. A thiazide diuretic, for example, initially increases Na+ and water excretion by reducing Na+ transport in the distal tubule. However, the diuresis is attenuated over a period of days, because the ensuing volume depletion enhances Na+ reabsorption both in the collecting tubules (via aldosterone) and in the proximal tubule (in part via angiotensin II) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15766/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The net effect is the establishment within one week of a new steady state in which the plasma volume is somewhat diminished, but",
"    <strong>",
"     Na+ excretion is again equal to intake",
"    </strong>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15766/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6868?source=see_link\">",
"     \"Time course of loop and thiazide diuretic-induced electrolyte complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measurement of urinary Na+ excretion is also important when evaluating patients with recurrent kidney stones. A 24-h urine collection is typically obtained in this setting to determine if calcium or uric acid excretion is increased, both of which can predispose to stone formation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15766/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. However, the tubular reabsorption of both calcium and uric acid is indirectly linked to that of Na+. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29033?source=see_link\">",
"     \"Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown\"",
"    </a>",
"    .) Thus, the increased Na+ reabsorption in hypovolemia can mask the presence of underlying hypercalciuria or hyperuricosuria [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15766/abstract/11\">",
"     11",
"    </a>",
"    ]. In general, Na+ excretion above 75 to 100",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    indicates that volume depletion is not a limiting factor for calcium or uric acid excretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite its usefulness, there are some pitfalls in relying upon the measurement of Na+ excretion as an index of volume status. A low urine Na+ concentration, for example, may be seen in normovolemic patients who have selective renal or glomerular ischemia due to bilateral renal artery stenosis or acute glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15766/abstract/2,12\">",
"     2,12",
"    </a>",
"    ]. On the other hand, a defect in tubular Na+ reabsorption can lead to a high rate of Na+ excretion, despite the presence of volume depletion. This can occur with the use of diuretics&dagger;, in aldosterone deficiency, or in advanced renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15766/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    &dagger; Although chronic diuretic use does not prevent attainment of a new steady state, urinary Na+ excretion that is equal to intake is still inappropriately high in a hypovolemic patient.",
"   </p>",
"   <p>",
"    The urine Na+ concentration can also be influenced by the rate of water reabsorption. This can be exemplified by central diabetes insipidus, a disorder in which a deficiency of antidiuretic hormone (ADH) can lead to a urine output exceeding 10",
"    <span class=\"nowrap\">",
"     L/day.",
"    </span>",
"    In this setting, the daily excretion of 100 meq of Na+ will be associated with a urine Na+ concentration of 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or less, incorrectly suggesting the presence of volume depletion. Conversely, a high rate of water reabsorption can raise the urine Na+ concentration and mask the presence of hypovolemia. To remove the effect of water reabsorption, the renal handling of Na+ can be evaluated directly by calculating the fractional excretion of Na+ (FENa).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fractional excretion of sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FENa can be calculated from a random urine specimen [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15766/abstract/2,3,14\">",
"     2,3,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; quantity of Na+ excreted",
"    <br/>",
"    &nbsp; &nbsp;FENa (%) &nbsp; = &nbsp; &mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash; &nbsp; x &nbsp;100",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;quantity of Na+ filtered",
"   </p>",
"   <p>",
"    The quantity of Na+ excreted is equal to the product of the urine Na+ concentration UNa and the urine flow rate (V); the quantity of Na+ filtered is equal to the product of the plasma Na+ concentration PNa and the glomerular filtration rate (or creatinine clearance, which is equal to Ucr &nbsp;x &nbsp;V &divide; Pcr). Thus,",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; UNa &nbsp;x &nbsp;V",
"    <br/>",
"    &nbsp; &nbsp;FENa &nbsp; &nbsp;= &nbsp; &nbsp; &mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash; &nbsp; x &nbsp;100",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; PNa &nbsp;x &nbsp;(Ucr &nbsp;x &nbsp;V &divide; Pcr)",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; UNa &nbsp;x &nbsp;Pcr",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; = &nbsp; &nbsp; &mdash;&mdash;&mdash;&mdash;&mdash;&mdash; &nbsp; x &nbsp;100",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; PNa &nbsp;x &nbsp;Ucr",
"    <br/>",
"    <br/>",
"   </p>",
"   <p>",
"    (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?25/13/25809?source=see_link\">",
"     calculator 1",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    , or for standard units, (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?24/28/25025?source=see_link\">",
"     calculator 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The primary use of the FENa &nbsp;is in patients with acute renal failure. As described above, a low urine Na+ concentration favors the diagnosis of volume depletion, whereas a high value points toward acute tubular necrosis. However, a level between 20 and 40",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    may be seen with either disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15766/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This overlap, which is due in part to variations in the rate of water reabsorption, can be minimized by calculating the FENa [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15766/abstract/2,3,14\">",
"     2,3,14",
"    </a>",
"    ]. Na+ reabsorption is appropriately enhanced in hypovolemic states, and the FENa &nbsp;is usually less than 1 percent; i.e., more than 99 percent of the filtered Na+ has been reabsorbed. In contrast, tubular damage leads to an FENa &nbsp;in excess of 2 to 3 percent in most patients with acute tubular necrosis.",
"   </p>",
"   <p>",
"    There are, however, exceptions to this general rule as the FENa may be less than 1 percent when acute tubular necrosis is superimposed upon chronic effective volume depletion (as occurs in hepatic cirrhosis, heart failure, and burns) or when it is induced by radiocontrast media or heme pigment deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15766/abstract/1,15-17\">",
"     1,15-17",
"    </a>",
"    ]. The mechanism by which this occurs is uncertain, although tubular function may be better preserved in these disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15766/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=see_link\">",
"     \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major limitation in the use of the FENa is that it is dependent upon the amount of Na+ filtered and therefore",
"    <strong>",
"     the dividing line between volume depletion and normovolemia is not always 1 percent",
"    </strong>",
"    . This can be best appreciated in patients with normal renal function. If the GFR is 180",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    (125",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    and the plasma Na+ concentration is 150",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    then 27,000 meq of Na+ will be filtered each day. As a result, the FENa will always be under 1 percent as long as daily Na+ intake is in the usual range of 125 to 250 meq. Since patients with relatively normal renal function should be able to lower daily Na+ excretion to less than 20",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    in the presence of volume depletion, the FENa should be less than 0.2 percent in this setting. A FENa of 0.5 percent is indicative of normovolemia not volume depletion in such a patient unless there is renal salt wasting. In comparison, a FENa of 0.5 percent does reflect volume depletion in advanced renal failure, a condition in which the GFR and therefore the filtered Na+ load are markedly reduced. If, for example, the GFR is only 10 percent of normal, then the filtered Na+ load is 2700",
"    <span class=\"nowrap\">",
"     meq/day;",
"    </span>",
"    0.5 percent of this quantity is equal to only 14 meq of Na+ excreted per day.",
"   </p>",
"   <p>",
"    The FENa and the UNa are difficult to interpret with concurrent diuretic therapy, since the ensuing natriuresis will raise these values even in patients who are hypovolemic. Although not widely available, measurement of the fractional clearance of endogenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    (which is present in trace amounts) may circumvent this problem. Lithium is primarily reabsorbed in the proximal tubule, which has two important consequences: proximal reabsorption is increased and therefore lithium excretion is reduced in hypovolemic states; and lithium excretion is not significantly increased by loop diuretics. The fractional excretion of lithium (FELi) is approximately 20 percent in healthy controls. In one report of patients with acute renal failure, a value below 15 percent (and usually below 10 percent) was highly suggestive of prerenal disease, independent of diuretic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15766/abstract/18\">",
"     18",
"    </a>",
"    ]. In comparison, the mean FELi was 26 percent in ATN.",
"   </p>",
"   <p>",
"    Given the usual lack of ability to measure trace",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , other markers for proximal function have been evaluated. Uric acid handling occurs almost entirely in the proximal tubule (see page 00) and the fractional excretion of uric acid is not affected by loop diuretic therapy. In the study noted above, values below 12 percent were suggestive of prerenal disease (sensitivity 68 percent, specificity 78 percent), while values above 20 percent were suggestive of ATN (sensitivity 96 percent, specificity only 33 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15766/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CHLORIDE EXCRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chloride is reabsorbed with sodium throughout the nephron (see Chaps. 3 to 5). As a result, the rate of excretion of these ions is usually similar, and measurement of the urine Cl- concentration generally adds little to the information obtained from the more routinely measured urine Na+ concentration.",
"   </p>",
"   <p>",
"    However, as many as 30 percent of hypovolemic patients have more than a",
"    <span class=\"nowrap\">",
"     15-meq/L",
"    </span>",
"    difference between the urine Na+ and Cl- &nbsp;concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15766/abstract/19\">",
"     19",
"    </a>",
"    ]. This is due to the excretion of Na+ with another anion (such as HCO3- or carbenicillin) or to the excretion of Cl- &nbsp;with another cation (such as NH4+ in metabolic acidosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15766/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Thus, it may be helpful to measure the urine Cl- concentration in a patient who seems to be volume depleted, but has a somewhat elevated urine Na+ concentration.",
"   </p>",
"   <p>",
"    This most often occurs in metabolic alkalosis, in which acid-base balance can be restored by urinary excretion of the excess HCO3- as NaHCO3. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39479?source=see_link\">",
"     \"Clinical manifestations and evaluation of metabolic alkalosis\"",
"    </a>",
"    .) Many of these patients, however, are volume depleted due to vomiting or diuretic use. To the degree that the hypovolemic stimulus to Na+ retention predominates, there will be low Na+ and HCO3- levels in the urine and persistence of the alkalosis. If, on the other hand, there is a relatively mild volume deficit as compared to the severity of the alkalosis, some NaHCO3 will be excreted, thereby elevating the urine Na+ concentration (in some cases to over 100",
"    <span class=\"nowrap\">",
"     meq/L).",
"    </span>",
"    In comparison, the urine Cl- concentration will remain appropriately low (unless some diuretic effect persists), since there is no defect in the reabsorption of NaCl.",
"   </p>",
"   <p>",
"    Another setting in which measurement of the urine Cl- concentration may be helpful is in patients with a normal anion gap metabolic acidosis (see Chap. 19) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15766/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In the absence of renal failure, this problem is most often due to diarrhea or to one of the forms of renal tubular acidosis (RTA). The normal response to acidemia is to increase urinary acid excretion, primarily as NH4+. When urine NH4+ levels are high, the urine anion gap",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Urine anion gap &nbsp; = &nbsp; ([Na+] &nbsp;+ &nbsp;[K+]) &nbsp;- &nbsp;[Cl-]",
"   </p>",
"   <p>",
"    will have a negative value, since the Cl- concentration will exceed that of Na+ and K+ by the approximate amount of NH4+ in the urine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11558?source=see_link\">",
"     \"Urine anion and osmolal gaps in metabolic acidosis\"",
"    </a>",
"    .) Thus, the urine Cl- concentration may be inappropriately high in diarrhea-induced hypovolemia because of the need to maintain electroneutrality as NH4+ excretion is enhanced [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15766/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In comparison, urinary acidification is impaired in RTA, leading to a low level of NH4+ excretion and a positive value for the urine anion gap [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15766/abstract/21\">",
"     21",
"    </a>",
"    ]. The urine pH also will be inappropriately high (&gt;5.3) in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     POTASSIUM EXCRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potassium excretion varies appropriately with intake, a response that is mediated primarily by aldosterone and a direct effect of the plasma K+ concentration &nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11657?source=see_link\">",
"     \"Chapter 12B: Renal potassium excretion\"",
"    </a>",
"    ). If K+ depletion occurs, urinary K+ excretion can fall to a minimum of 5 to 25",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15766/abstract/23\">",
"     23",
"    </a>",
"    ]. As a result, measurement of K+ excretion can aid in the diagnosis of unexplained hypokalemia. An appropriately low value suggests either extrarenal losses (usually from the gastrointestinal tract) or the use of diuretics (if the collection has been obtained after the diuretic effect has worn off). In comparison, the excretion of more than 25 meq of K+ per day indicates at least a component of renal K+ wasting.",
"   </p>",
"   <p>",
"    Measurement of K+ excretion is less helpful in patients with hyperkalemia. If K+ intake is increased slowly, normal subjects can take in and excrete more than 400 meq of K+ per day without a substantial elevation in the plasma K+ concentration (normal daily intake is 40 to 120 meq) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15766/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Thus, chronic hyperkalemia must be associated with a defect in urinary K+ excretion, since normal renal function would result in the rapid excretion of the excess K+. As a result, the urine K+ concentration will be inappropriately low in this setting, most often due to renal failure or hypoaldosteronism (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=see_link\">",
"     \"Causes and evaluation of hyperkalemia in adults\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14355?source=see_link\">",
"     \"Chapter 13B: Meaning of urine osmolality and pH\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose BD. Pathophysiology of Renal Disease, 2d ed., McGraw-Hill, New York, 1987, p. 82.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15766/abstract/2\">",
"      Miller TR, Anderson RJ, Linas SL, et al. Urinary diagnostic indices in acute renal failure: a prospective study. Ann Intern Med 1978; 89:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15766/abstract/3\">",
"      Espinel CH, Gregory AW. Differential diagnosis of acute renal failure. Clin Nephrol 1980; 13:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15766/abstract/4\">",
"      Cutler JA, Follmann D, Allender PS. Randomized trials of sodium reduction: an overview. Am J Clin Nutr 1997; 65:643S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15766/abstract/5\">",
"      Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure. I&mdash;An analysis of observational data among populations; III&mdash;Analysis of data of salt reduction. Br Med J 1991; 302:811,819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15766/abstract/6\">",
"      Wilcox CS, Guzman NJ, Mitch WE, et al. Na+, K+, and BP homeostasis in man during furosemide: effects of prazosin and captopril. Kidney Int 1987; 31:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15766/abstract/7\">",
"      Bock HA, Stein JH. Diuretics and the control of extracellular fluid volume: role of counterregulation. Semin Nephrol 1988; 8:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15766/abstract/8\">",
"      Maronde R Milgrom, M, Vlachakis, ND, Chan, L. Response of thiazide-induced hypokalemia to amiloride. J Am Med Assoc 1983; 249:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15766/abstract/9\">",
"      Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med 1992; 327:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15766/abstract/10\">",
"      Parks JH, Coe FL. A urinary calcium-citrate index for the evaluation of nephrolithiasis. Kidney Int 1986; 30:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15766/abstract/11\">",
"      Muldowney FP, Freaney R, Moloney MF. Importance of dietary sodium in the hypercalciuria syndrome. Kidney Int 1982; 22:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15766/abstract/12\">",
"      Besarab A, Brown RS, Rubin NT, et al. Reversible renal failure following bilateral renal artery occlusive disease: clinical features, pathology, and the role of surgical revascularization. J Am Med Assoc 1976; 235:2838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15766/abstract/13\">",
"      Danovitch GM, Bourgoignie JJ, Bricker NS. Reversibility of the \"salt-losing\" tendency of chronic renal failure. N Engl J Med 1977; 296:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15766/abstract/14\">",
"      Steiner RW. Interpreting the fractional excretion of sodium. Am J Med 1984; 77:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15766/abstract/15\">",
"      Planas M, Wachtel T, Frank H, Henderson LW. Characterization of acute renal failure in the burned patient. Arch Intern Med 1982; 142:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15766/abstract/16\">",
"      Diamond JR, Yoburn DC. Nonoliguric acute renal failure associated with a low fractional excretion of sodium. Ann Intern Med 1982; 96:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15766/abstract/17\">",
"      Fang LS, Sirota RA, Ebert TH, Lichtenstein NS. Low fractional excretion of sodium with contrast media-induced acute renal failure. Arch Intern Med 1980; 140:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15766/abstract/18\">",
"      Steinh&auml;uslin F, Burnier M, Magnin JL, et al. Fractional excretion of trace lithium and uric acid in acute renal failure. J Am Soc Nephrol 1994; 4:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15766/abstract/19\">",
"      Sherman RA, Eisinger RP. The use (and misuse) of urinary sodium and chloride measurements. J Am Med Assoc 1982; 247:3121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15766/abstract/20\">",
"      Kamel KS, Ethier JH, Richardson RM, et al. Urine electrolytes and osmolality: when and how to use them. Am J Nephrol 1990; 10:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15766/abstract/21\">",
"      Batlle DC, Hizon M, Cohen E, et al. The use of the urinary anion gap in the diagnosis of hyperchloremic metabolic acidosis. N Engl J Med 1988; 318:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15766/abstract/22\">",
"      Goldstein MB, Bear R, Richardson RM, et al. The urine anion gap: a clinically useful index of ammonium excretion. Am J Med Sci 1986; 292:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15766/abstract/23\">",
"      SQUIRES RD, HUTH EJ. Experimental potassium depletion in normal human subjects. I. Relation of ionic intakes to the renal conservation of potassium. J Clin Invest 1959; 38:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15766/abstract/24\">",
"      Talbott JH, Schwab RS. Recent advances in the biochemistry and therapeusis of potassium salts. N Engl J Med 1940; 222:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15766/abstract/25\">",
"      Rabelink TJ, Koomans HA, Hen&eacute; RJ, Dorhout Mees EJ. Early and late adjustment to potassium loading in humans. Kidney Int 1990; 38:942.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7265 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-5849588C53-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_25_15766=[""].join("\n");
var outline_f15_25_15766=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SODIUM EXCRETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fractional excretion of sodium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Limitations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CHLORIDE EXCRETION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      POTASSIUM EXCRETION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7265\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7265|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/42/25259\" title=\"table 1\">",
"      Urine chemistries",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?25/13/25809?source=related_link\" title=\"calculator 1\">",
"      Calculator: Fractional excretion of sodium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?24/28/25025?source=related_link\" title=\"calculator 2\">",
"      Calculator: Fractional excretion of sodium (SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11657?source=related_link\">",
"      Chapter 12B: Renal potassium excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14355?source=related_link\">",
"      Chapter 13B: Meaning of urine osmolality and pH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6744?source=related_link\">",
"      Chapter 8C: Regulation of renal Na+ excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39479?source=related_link\">",
"      Clinical manifestations and evaluation of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29033?source=related_link\">",
"      Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=related_link\">",
"      Evaluation of the patient with hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=related_link\">",
"      Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6868?source=related_link\">",
"      Time course of loop and thiazide diuretic-induced electrolyte complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11558?source=related_link\">",
"      Urine anion and osmolal gaps in metabolic acidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_25_15767="Causes of hypophosphatemia";
var content_f15_25_15767=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes of hypophosphatemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/25/15767/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/25/15767/contributors\">",
"     Zalman S Agus, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/25/15767/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/25/15767/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/25/15767/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/25/15767/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/25/15767/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported prevalence of hypophosphatemia varies widely, depending upon the patient population surveyed and the concentration of serum phosphorus used to define hypophosphatemia. Up to five percent of hospitalized patients may have low serum phosphate concentrations (less than 2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [0.80",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    although prevalences of over 30 to 50 percent have been reported in alcoholic patients, and patients with severe sepsis or trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Profound hypophosphatemia (less than 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [0.32",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    which can lead to physiological disturbances and symptoms, is much less common [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32659?source=see_link\">",
"     \"Signs and symptoms of hypophosphatemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are three major mechanisms by which hypophosphatemia can occur (",
"    <a class=\"graphic graphic_table graphicRef71616 \" href=\"UTD.htm?24/38/25195\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Redistribution of phosphate from the extracellular fluid into cells",
"     </li>",
"     <li>",
"      Decreased intestinal absorption of phosphate",
"     </li>",
"     <li>",
"      Increased urinary phosphate excretion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The causes of hypophosphatemia will be reviewed here. The diagnosis and treatment of hypophosphatemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2167?source=see_link\">",
"     \"Diagnosis and treatment of hypophosphatemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INTERNAL REDISTRIBUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stimulation of glycolysis increases the formation of phosphorylated carbohydrate compounds in the liver and skeletal muscle. The source of this phosphate is the inorganic phosphate in the extracellular fluid; as a result, serum phosphate concentrations (and urinary phosphate excretion) fall rapidly. This occurs in several situations:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Increased insulin secretion, particularly during refeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal subjects, the administration of insulin or glucose (which stimulates endogenous insulin release) results in only a small decrease in serum phosphate concentrations. Administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    and epinephrine can also cause mild hypophosphatemia by a similar mechanism.",
"   </p>",
"   <p>",
"    If, however, there is underlying phosphate depletion, then severe hypophosphatemia may ensue. It is most likely to occur during treatment of patients with diabetic ketoacidosis or nonketotic hyperglycemia (in which the glucose-induced osmotic diuresis results in loss of phosphate in the urine), during carbohydrate refeeding in malnourished patients with alcoholism or anorexia nervosa [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], and in patients receiving hyperalimentation. Concurrent respiratory alkalosis may also contribute in alcoholic patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Serum phosphate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28324?source=see_link\">",
"     \"Hypophosphatemia in the alcoholic patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=see_link\">",
"     \"Eating disorders: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Acute respiratory alkalosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fall in partial pressure of carbon dioxide during acute respiratory alkalosis results in a similar change in the cells, because carbon dioxide readily diffuses across cell membranes. The resulting rise in intracellular pH stimulates phosphofructokinase activity which in turn stimulates glycolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/8\">",
"     8",
"    </a>",
"    ]. Extreme hyperventilation (to pCO2 &lt;20 mm Hg) in normal subjects can lower serum phosphate concentrations to below 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.32",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/9\">",
"     9",
"    </a>",
"    ], and it is probably the most common cause of marked hypophosphatemia in hospitalized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/4\">",
"     4",
"    </a>",
"    ]. Less pronounced hypophosphatemia may occur during the increase in ventilation after successful treatment of severe asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/10\">",
"     10",
"    </a>",
"    ]. The effects of mild respiratory alkalosis to induce falls in serum phosphate of &gt;.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    require concomitant glucose infusions and may persist after hyperventilation ceases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Respiratory alkalosis also may be the precipitating factor in the hypophosphatemia-induced acute rhabdomyolysis that can occur in alcoholic patients. In these patients, however, the underlying hypophosphatemia may be masked initially due to the release of phosphate from the injured muscle cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28324?source=see_link\">",
"     \"Hypophosphatemia in the alcoholic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hungry bone syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parathyroidectomy (for hyperparathyroidism) or rarely thyroidectomy (for hyperthyroidism) in patients with preexisting osteopenia can rarely result in marked deposition of calcium and phosphate in bone in the immediate postoperative period. This phenomenon, called the \"hungry bone\" syndrome, may be associated with marked hypocalcemia (which may be symptomatic) and hypophosphatemia. A similar phenomenon may occur after treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3287?source=see_link\">",
"     \"Hungry bone syndrome following parathyroidectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DECREASED INTESTINAL ABSORPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal adults are in phosphate balance. Their dietary intake of phosphate, which usually ranges from 800 to 1500",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    is usually well in excess of gastrointestinal losses, and therefore variations in intake usually have little effect on phosphate homeostasis. There is little regulation of gut absorption (although calcitriol, the most active metabolite of vitamin D, does have some stimulatory effect). Approximately 80 percent of dietary phosphate is absorbed in the small intestine. In addition, 150 to 200 mg per day is secreted in the colon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Inadequate intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poor intake alone is rarely responsible for severe phosphate depletion because of rapid renal adaptation, whereby renal tubular phosphate reabsorption approaches 100 percent, and therefore urinary phosphate excretion approaches zero [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. If, however, phosphate deprivation is prolonged and severe (intake of less than 100 mg per day), then continued colonic phosphate secretion can lead to hypophosphatemia. More often, poor intake is combined with chronic diarrhea to cause markedly negative phosphate balance. These patients may also have poor intake or malabsorption of vitamin D. The secondary hyperparathyroidism induced by vitamin D deficiency can worsen phosphate depletion by increasing urinary phosphate excretion. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Increased urinary excretion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Total starvation alone does not cause hypophosphatemia because of the lack of insulin and the associated increase in cell catabolism that results in phosphate release from cells. Refeeding of starved patients, however, can cause hypophosphatemia, unless phosphate is provided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antacids containing aluminum or magnesium",
"    </span>",
"    &nbsp;&mdash;&nbsp;These drugs cause net loss of phosphate from the body by binding to both ingested and secreted phosphate; with the resulting formation of insoluble aluminum or magnesium phosphate salts. Prolonged high-dose treatment with these drugs can cause hypophosphatemia, osteomalacia, and myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/15\">",
"     15",
"    </a>",
"    ]. This has become less of a problem since the availability of other, more convenient drugs to treat acid-peptic disease such as histamine H2-receptor blockers and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    . Hypophosphatemia related to prior antacid use is a particular problem postoperatively in patients who undergo hepatic resection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/16\">",
"     16",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     Calcium carbonate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/48/39685?source=see_link\">",
"     calcium acetate",
"    </a>",
"    can be used to treat hyperphosphatemia in patients with advanced renal failure and inappropriate or excessive use in that population (particularly in malnourished patients) may induce hypophosphatemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Steatorrhea and chronic diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Steatorrhea or chronic diarrhea can cause mild to moderate hypophosphatemia, due to decreased phosphate absorption from the gut and renal phosphate wasting, the latter caused by secondary hyperparathyroidism induced by concomitant vitamin D deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INCREASED URINARY EXCRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The kidney exerts a major influence on phosphate balance. Renal phosphate transport occurs in the proximal tubule (60 to 70 percent of the filtered load being reabsorbed) and in the distal tubule (10 to 15 percent of the filtered load being reabsorbed) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Phosphate reabsorption is linked to sodium reabsorption via a sodium-phosphate cotransporter in the luminal membrane. This transporter uses the favorable inward concentration gradient for sodium (the cell sodium concentration is less than 25",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    well below the 145",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    concentration in the tubular lumen) to drive the active reabsorption of phosphate.",
"   </p>",
"   <p>",
"    Physiologic regulators of renal tubular phosphate reabsorption include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum phosphate concentration &mdash; Mild phosphate depletion stimulates phosphate reabsorption via the sodium-phosphate cotransporters in the proximal tubule [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. Phosphate depletion also leads to increased synthesis of new transporters, which increases tubular phosphate reabsorption.",
"     </li>",
"     <li>",
"      Parathyroid hormone &mdash; Parathyroid hormone (PTH) increases phosphate excretion by diminishing activity of sodium-phosphate cotransporters [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/13,14\">",
"       13,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Phosphatonins &mdash; Phosphatonins such as fibroblast growth factor 23 (FGF-23) and secreted frizzled related protein-4 (sFRP-4) decrease phosphate reabsorption by sodium-phosphate cotransporters [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/17-20\">",
"       17-20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A gastrointestinal sensor of dietary phosphate may lead to direct enhancement of renal phosphate excretion by an as yet unknown mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hypophosphatemia-induced increase in phosphate reabsorption protects against further phosphate losses. If inappropriately increased excretion persists, it is due to one of two factors: hyperparathyroidism; or an intrinsic defect in phosphate transport.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Primary and secondary hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any cause of hypersecretion of PTH can lead to hypophosphatemia. This occurs in primary hyperparathyroidism (in which hypercalcemia is usually the most prominent abnormality) and in secondary hyperparathyroidism induced by any of the causes of vitamin D deficiency. Most patients with primary hyperparathyroidism have mild hypophosphatemia. It may be more severe in those with vitamin D deficiency and secondary hyperparathyroidism, because they have not only increased urinary phosphate excretion but also decreased gastrointestinal phosphate absorption. Animal models suggest that the mechanism by which this occurs may be due, in part, to a PTH-induced increase in FGF-23 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Vitamin D deficiency or resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D deficiency can cause hypophosphatemia both by decreasing gastrointestinal phosphate absorption and by causing hypocalcemia and secondary hyperparathyroidism, resulting in increased urinary phosphate excretion. Vitamin D deficiency can occur as a result of decreased intake or absorption, reduced sun exposure, increased hepatic catabolism, decreased endogenous synthesis, or end-organ resistance (",
"    <a class=\"graphic graphic_table graphicRef58837 \" href=\"UTD.htm?37/48/38667\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38184?source=see_link\">",
"     \"Causes of vitamin D deficiency and resistance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Primary renal phosphate wasting",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several rare syndromes characterized by isolated renal phosphate wasting. The resulting hypophosphatemia is the primary cause of rickets and, in contrast to vitamin D deficiency or resistance, hypocalcemia is not present.",
"   </p>",
"   <p>",
"    The underlying abnormalities of some of these syndromes have been characterized [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In X-linked hypophosphatemic rickets (which had been called vitamin D-resistant rickets), the defect in proximal tubular phosphate transport is due to a mutation in the PHEX gene [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/24\">",
"       24",
"      </a>",
"      ]. This gene encodes an endopeptidase that degrades and inactivates hormone-like substances (called phosphatonins) that promote phosphate excretion and impair bone mineralization. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=see_link&amp;anchor=H2#H2\">",
"       \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\", section on 'X-linked'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A few reports have described a renal phosphate-wasting syndrome with rickets or osteomalacia that is transmitted as an autosomal dominant trait. This disorder is known as autosomal dominant hypophosphatemic rickets and results from mutations in the fibroblast growth factor 23 (FGF23) gene on chromosome 12p13. FGF23 inhibits renal phosphate reabsorption and calcitriol synthesis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=see_link&amp;anchor=H10#H10\">",
"       \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\", section on 'Autosomal dominant'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mutations in the sodium-phosphate cotransporter gene SLC34A3 produce striking dysfunction of the type 2a sodium-phosphate cotransporter and may lead to an autosomal recessive syndrome of hereditary hypophosphatemic rickets and hypercalciuria. Mutations of the sodium-hydrogen exchanger regulatory factor 1 (NHERF1), which regulates activity of the sodium-phosphate cotransporter, have also been associated with impaired phosphate reabsorption and hypophosphatemia [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=see_link&amp;anchor=H16#H16\">",
"       \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\", section on 'Hypophosphatemic rickets with hypercalciuria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A similar syndrome occurs as an acquired disorder in patients with tumor-induced osteomalacia. These patients usually have tumors of mesenchymal origin, often a sclerosing type of hemangiopericytoma, that produce a phosphaturic hormone(s) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/26\">",
"       26",
"      </a>",
"      ]. Among the factors that may be important are FGF-23, matrix extracellular phosphoglycoprotein (MEPE), and frizzled-related protein-4. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=see_link&amp;anchor=H22#H22\">",
"       \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\", section on 'Tumor-induced osteomalacia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rarely, significant renal phosphate wasting is observed in patients with fibrous",
"      <span class=\"nowrap\">",
"       dysplasia/McCune-Albright",
"      </span>",
"      syndrome, disorders that result from mutations in the alpha subunit of the stimulatory G protein. Excess production of FGF-23 has been found in some of these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some patients with hypophosphatemia and inappropriate urinary phosphate wasting also have nephrolithiasis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      osteoporosis. Although mutations in the type 2a sodium-phosphate cotransporter have been described in such patients, the extent of their association with the abnormalities in renal phosphate and calcium handling is uncertain [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/28,29\">",
"       28,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypophosphatemia is a common complication post-transplantation, and may be due in part to tertiary hyperparathyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/30-32\">",
"       30-32",
"      </a>",
"      ]. Elevated levels of FGF23 may also contribute to this complication [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/33\">",
"       33",
"      </a>",
"      ]. It appears to resolve by one year post-transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=see_link\">",
"       \"Parathyroid and mineral metabolism after renal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypophosphatemia and hyperphosphaturia are common in patients who have undergone a partial hepatectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/19,35,36\">",
"       19,35,36",
"      </a>",
"      ]. The mechanism is not known [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/19,36\">",
"       19,36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An autosomal recessive form of hypophosphatemia appears to be the result of mutations in the gene for dentin matrix protein 1 [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. This protein may help regulate the expression of FGF-23.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Fanconi syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Fanconi syndrome refers to a generalized impairment in proximal tubular function leading to urinary wasting of compounds normally reabsorbed in the proximal tubule. The consequences are hypophosphatemia (which can lead to osteomalacia), renal glucosuria, hypouricemia, aminoaciduria, and proximal renal tubular acidosis due to bicarbonate loss in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/39\">",
"     39",
"    </a>",
"    ]. Serum calcitriol concentrations are either low or inappropriately normal.",
"   </p>",
"   <p>",
"    The Fanconi syndrome is rare in adults. It is most often due to multiple myeloma (in which the immunoglobulin light chains are toxic to the renal tubules). In children, cystinosis, Wilson's disease, and hereditary fructose intolerance are the most common of the syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=see_link\">",
"     \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Miscellaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other factors that can increase urinary phosphate excretion are osmotic diuresis (most often due to glucosuria), proximally acting diuretics (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    and some thiazide diuretics that also have carbonic anhydrase inhibitory activity such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/32/1542?source=see_link\">",
"     metolazone",
"    </a>",
"    ), acute volume expansion (which diminishes proximal sodium reabsorption), and intravenous iron administration [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/40\">",
"     40",
"    </a>",
"    ]. Intravenous iron may increase phosphate excretion by causing an increase in circulating levels of FGF23 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Primary renal phosphate wasting'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Increased urinary phosphate excretion and hypophosphatemia have also been reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    mesylate, a drug used in the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15767/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. The mechanism is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Up to 5 percent of hospitalized patients have low serum phosphate concentrations (defined as less than 2.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [0.80",
"      <span class=\"nowrap\">",
"       mmol/L]);",
"      </span>",
"      prevalences of over 30 to 50 percent have been reported in alcoholic patients, and patients with severe sepsis or trauma. Profound hypophosphatemia (defined as less than 1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [0.32",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      is much less common. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The three major mechanisms that cause hypophosphatemia include the redistribution of phosphate from the extracellular fluid into cells; decreased intestinal absorption of phosphate; and increased urinary phosphate excretion. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The redistribution of phosphate occurs as a result of the stimulation of glycolysis by the administration of insulin, glucose,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"      and epinephrine; during acute respiratory alkalosis; and as a result of hungry bone syndrome following parathyroidectomy or thyroidectomy in patients with preexisting osteopenia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Internal redistribution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Decreased intestinal absorption of phosphate may be caused by poor intake combined with chronic diarrhea or by prolonged use of antacids that bind to both ingested and secreted phosphate. Poor intake alone is rarely a cause of significant hypophosphatemia. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Decreased intestinal absorption'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased urinary excretion of phosphate occurs as a result of hyperparathyroidism, vitamin D deficiency, and several rare syndromes that cause isolated renal phosphate wasting. The Fanconi syndrome is a generalized impairment in proximal tubular function that causes urinary wasting of phosphate as well as other compounds. In adults, the Fanconi syndrome is most often due to multiple myeloma; in children, cystinosis, Wilson's disease, and hereditary fructose intolerance are the most common causes of the syndrome. Other factors that may increase urinary phosphate excretion include osmotic diuresis, proximally acting diuretics, acute volume expansion, and intravenous iron administration. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Increased urinary excretion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypophosphatemia is a common complication post-transplantation (possibly due in part to tertiary hyperparathyroidism) and following partial hepatectomy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Primary renal phosphate wasting'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/1\">",
"      Larsson L, Rebel K, S&ouml;rbo B. Severe hypophosphatemia--a hospital survey. Acta Med Scand 1983; 214:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/2\">",
"      King AL, Sica DA, Miller G, Pierpaoli S. Severe hypophosphatemia in a general hospital population. South Med J 1987; 80:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/3\">",
"      Gaasbeek A, Meinders AE. Hypophosphatemia: an update on its etiology and treatment. Am J Med 2005; 118:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/4\">",
"      Halevy J, Bulvik S. Severe hypophosphatemia in hospitalized patients. Arch Intern Med 1988; 148:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/5\">",
"      Subramanian R, Khardori R. Severe hypophosphatemia. Pathophysiologic implications, clinical presentations, and treatment. Medicine (Baltimore) 2000; 79:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/6\">",
"      Paterson CR. Hypophosphataemia: a dangerous disorder. Nutrition 1996; 12:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/7\">",
"      Marinella MA. Refeeding syndrome and hypophosphatemia. J Intensive Care Med 2005; 20:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/8\">",
"      Brautbar N, Leibovici H, Massry SG. On the mechanism of hypophosphatemia during acute hyperventilation: evidence for increased muscle glycolysis. Miner Electrolyte Metab 1983; 9:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/9\">",
"      MOSTELLAR ME, TUTTLE EP Jr. EFFECTS OF ALKALOSIS ON PLASMA CONCENTRATION AND URINARY EXCRETION OF INORGANIC PHOSPHATE IN MAN. J Clin Invest 1964; 43:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/10\">",
"      Laaban JP, Waked M, Laromiguiere M, et al. Hypophosphatemia complicating management of acute severe asthma. Ann Intern Med 1990; 112:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/11\">",
"      Paleologos M, Stone E, Braude S. Persistent, progressive hypophosphataemia after voluntary hyperventilation. Clin Sci (Lond) 2000; 98:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/12\">",
"      Nowack R, Wachtler P. Hypophosphatemia and hungry bone syndrome in a dialysis patient with secondary hyperparathyroidism treated with cinacalcet--proposal for an improved monitoring. Clin Lab 2006; 52:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/13\">",
"      Murer H. Homer Smith Award. Cellular mechanisms in proximal tubular Pi reabsorption: some answers and more questions. J Am Soc Nephrol 1992; 2:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/14\">",
"      Murer H, L&ouml;tscher M, Kaissling B, et al. Renal brush border membrane Na/Pi-cotransport: molecular aspects in PTH-dependent and dietary regulation. Kidney Int 1996; 49:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/15\">",
"      Lotz M, Zisman E, Bartter FC. Evidence for a phosphorus-depletion syndrome in man. N Engl J Med 1968; 278:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/16\">",
"      Buell JF, Berger AC, Plotkin JS, et al. The clinical implications of hypophosphatemia following major hepatic resection or cryosurgery. Arch Surg 1998; 133:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/17\">",
"      Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006; 91:3144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/18\">",
"      Myamoto, K, Ito, M, Tatsumi, S, et al. New aspects of renal phosphate reabsorption: the type IIc sodium-dependent phosphate transporter. Am J Nephrology 2007; 27:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/19\">",
"      Nafidi O, Lapointe RW, Lepage R, et al. Mechanisms of renal phosphate loss in liver resection-associated hypophosphatemia. Ann Surg 2009; 249:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/20\">",
"      Gattineni J, Baum M. Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism. Pediatr Nephrol 2010; 25:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/21\">",
"      Berndt T, Thomas LF, Craig TA, et al. Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption. Proc Natl Acad Sci U S A 2007; 104:11085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/22\">",
"      Kawata T, Imanishi Y, Kobayashi K, et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 2007; 18:2683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/23\">",
"      Tenenhouse HS, Murer H. Disorders of renal tubular phosphate transport. J Am Soc Nephrol 2003; 14:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/24\">",
"      A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 1995; 11:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/25\">",
"      Karim Z, G&eacute;rard B, Bakouh N, et al. NHERF1 mutations and responsiveness of renal parathyroid hormone. N Engl J Med 2008; 359:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/26\">",
"      Wilkins GE, Granleese S, Hegele RG, et al. Oncogenic osteomalacia: evidence for a humoral phosphaturic factor. J Clin Endocrinol Metab 1995; 80:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/27\">",
"      Riminucci M, Collins MT, Fedarko NS, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003; 112:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/28\">",
"      Pri&eacute; D, Huart V, Bakouh N, et al. Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med 2002; 347:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/29\">",
"      Lapointe JY, Tessier J, Paquette Y, et al. NPT2a gene variation in calcium nephrolithiasis with renal phosphate leak. Kidney Int 2006; 69:2261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/30\">",
"      Bhan I, Shah A, Holmes J, et al. Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'? Kidney Int 2006; 70:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/31\">",
"      Pande S, Ritter CS, Rothstein M, et al. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol 2006; 104:p23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/32\">",
"      Ghanekar H, Welch BJ, Moe OW, Sakhaee K. Post-renal transplantation hypophosphatemia: a review and novel insights. Curr Opin Nephrol Hypertens 2006; 15:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/33\">",
"      Evenepoel P, Naesens M, Claes K, et al. Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 2007; 7:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/34\">",
"      Evenepoel P, Meijers BK, de Jonge H, et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol 2008; 3:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/35\">",
"      Lee HW, Suh KS, Kim J, et al. Hypophosphatemia after live donor right hepatectomy. Surgery 2008; 144:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/36\">",
"      Salem RR, Tray K. Hepatic resection-related hypophosphatemia is of renal origin as manifested by isolated hyperphosphaturia. Ann Surg 2005; 241:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/37\">",
"      Lorenz-Depiereux, B, Bastepe, M, Benet-Pages, A, et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Gen 2006; 18:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/38\">",
"      Liu S, Zhou J, Tang W, et al. Pathogenic role of Fgf23 in Dmp1-null mice. Am J Physiol Endocrinol Metab 2008; 295:E254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/39\">",
"      Clarke BL, Wynne AG, Wilson DM, Fitzpatrick LA. Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features. Clin Endocrinol (Oxf) 1995; 43:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/40\">",
"      Okada M, Imamura K, Iida M, et al. Hypophosphatemia induced by intravenous administration of Saccharated iron oxide. Klin Wochenschr 1983; 61:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/41\">",
"      Schouten BJ, Hunt PJ, Livesey JH, et al. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab 2009; 94:2332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/42\">",
"      Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15767/abstract/43\">",
"      Owen S, Hatfield A, Letvak L. Imatinib and altered bone and mineral metabolism. N Engl J Med 2006; 355:627; author reply 628.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 830 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-6B4A64F196-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_25_15767=[""].join("\n");
var outline_f15_25_15767=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INTERNAL REDISTRIBUTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Increased insulin secretion, particularly during refeeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Acute respiratory alkalosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hungry bone syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DECREASED INTESTINAL ABSORPTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Inadequate intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antacids containing aluminum or magnesium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Steatorrhea and chronic diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INCREASED URINARY EXCRETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Primary and secondary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Vitamin D deficiency or resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Primary renal phosphate wasting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Fanconi syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Miscellaneous",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/830\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/830|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/38/25195\" title=\"table 1\">",
"      Causes of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/48/38667\" title=\"table 2\">",
"      Causes of vitamin D deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38184?source=related_link\">",
"      Causes of vitamin D deficiency and resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2167?source=related_link\">",
"      Diagnosis and treatment of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=related_link\">",
"      Eating disorders: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=related_link\">",
"      Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=related_link\">",
"      Hereditary hypophosphatemic rickets and tumor-induced osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3287?source=related_link\">",
"      Hungry bone syndrome following parathyroidectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28324?source=related_link\">",
"      Hypophosphatemia in the alcoholic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=related_link\">",
"      Parathyroid and mineral metabolism after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32659?source=related_link\">",
"      Signs and symptoms of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=related_link\">",
"      Treatment of hyperphosphatemia in chronic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_25_15768="Pacer nonsensing tutorial";
var content_f15_25_15768=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1046px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pacemaker malfunction - non-sensing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 152px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The second and fourth paced QRS complexes occur earlier than expected based upon the lower rate limit of the pacemaker. The pacemaker has failed to sense the preceding native complexes, and is therefore not inhibited by them. Thus, the pacemaker will fire and stimulate the atria or ventricles at its own predetermined rate, independently of the intrinsic rhythm. The interval between the native and paced complexes is variable while the intervals of the pacing spikes is constant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_25_15768=[""].join("\n");
var outline_f15_25_15768=null;
var title_f15_25_15769="Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis";
var content_f15_25_15769=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/25/15769/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/25/15769/contributors\">",
"     Andrew G Lee, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/25/15769/contributors\">",
"     Michael Wall, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/25/15769/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/25/15769/contributors\">",
"     Paul W Brazis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/25/15769/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/25/15769/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/25/15769/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic intracranial hypertension (IIH) is also commonly called pseudotumor cerebri. It is a disorder defined by clinical criteria that include symptoms and signs isolated to those produced by increased intracranial pressure (eg, headache, papilledema, vision loss), elevated intracranial pressure with normal cerebrospinal fluid composition, and no other cause of intracranial hypertension evident on neuroimaging or other evaluations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While once called benign intracranial hypertension, to distinguish it from secondary intracranial hypertension produced by a neoplastic malignancy, it is not a benign disorder. Many patients suffer from intractable, disabling headaches, and there is a risk of severe, permanent vision loss.",
"   </p>",
"   <p>",
"    While the pathogenesis of IIH is unknown, risk factors have been identified and many theories advanced as to its cause. The epidemiology and pathogenesis of IIH will be reviewed here. The clinical features, diagnosis, prognosis, and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=see_link\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/54/41833?source=see_link\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The annual incidence of IIH is 1 to 2 per 100,000 population [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. There is a higher incidence in obese women between the ages of 15 and 44 years (4 to 21 per 100,000) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. With the increasing obesity epidemic in the United States and in other parts of the world, the incidence and prevalence of IIH is rising [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;IIH is a disorder that primarily affects women of childbearing age who are overweight [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/3,4,6-10\">",
"     3,4,6-10",
"    </a>",
"    ]. In a prospective study of 50 consecutively-diagnosed IIH patients, 92 percent were women with a mean age of 31 years (range 11 to 58 years) and 94 percent were obese [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/9\">",
"     9",
"    </a>",
"    ]. Other case series in different geographic areas and ethnic groups report consistent findings [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/4,10-14\">",
"     4,10-14",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    IIH can also occur in males, in children as young as four months, in older patients (up to 88 years), and in patients who are not overweight [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. However, when symptoms occur in one of the less typical patient groups, the evaluation for secondary causes of intracranial hypertension is particularly important. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=see_link&amp;anchor=H12#H12\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors are somewhat different in prepubertal children compared with adults. The gender difference is not as apparent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/15,19-26\">",
"     15,19-26",
"    </a>",
"    ]. Also, prepubertal children with IIH are not more likely to be obese than the general age-matched population [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/19,20,23,24,26\">",
"     19,20,23,24,26",
"    </a>",
"    ]. In one report, older patients (44 to 88 years) with IIH were also more often male and less often obese than IIH patients in the more typical age range [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/27\">",
"     27",
"    </a>",
"    ]. Men with IIH have a similar age distribution as women, and obesity remains a risk factor but may be less prevalent than in women with IIH [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/11,16\">",
"     11,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recent weight gain may be a risk factor for IIH, according to case-control studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/7,9,10\">",
"     7,9,10",
"    </a>",
"    ]. In one series, there was an average reported weight gain of 1.8 kg over the two months preceding symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/9\">",
"     9",
"    </a>",
"    ]; in another, there was an average 20 lb weight gain over the preceding year compared to an average weight loss of 1.2 lb in controls [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Associated conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although IIH is, by definition, idiopathic, a number of systemic diseases, drugs, vitamin deficiencies and excesses, and hereditary conditions have been reported to be associated with IIH. Most patients with IIH do not have one of these conditions.",
"   </p>",
"   <p>",
"    The true link between these conditions and IIH is uncertain in many cases. In case-control studies, the prevalence of menstrual irregularities, pregnancy, antibiotic use, iron deficiency anemia, thyroid dysfunction, and oral contraceptive use were no different among cases versus controls [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. However, these studies were small (40 to 50 patients), which may have limited their ability to detect true associations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of medications and other exogenous substances have been linked to IIH. For some of these, the connection may be anecdotal. In other cases, evidence that supports a true association includes temporal proximity between drug initiation and IIH in a substantial number of patients, resolution with drug cessation or dose-lowering, lack of recurrence off medication,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reemergence of IIH with drug rechallenge. Such evidence appears to exist for growth hormone, tetracyclines, and retinoids.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Growth hormone appears to be associated with IIH in a dose-related manner [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/28-34\">",
"       28-34",
"      </a>",
"      ]. One 2007 study estimated the incidence of IIH in children treated with GH to be 27.7 per 100,000 treatment years. This complication usually develops within one year of initiation of therapy, but may appear after several years of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/35\">",
"       35",
"      </a>",
"      ]. IIH generally subsides with stopping growth hormone therapy; resuming at a lower dose is often successful. Other specific treatments for IIH may also be required [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=see_link\">",
"       \"Treatment of growth hormone deficiency in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tetracyclines, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       minocycline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      have been linked in a number of cases to IIH, but other risk factors are often present [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/36-45\">",
"       36-45",
"      </a>",
"      ]. When it occurs, IIH often appears shortly after onset of treatment (within a few weeks to months), but a more delayed-onset has been described. Drug withdrawal appears to be sufficient for treatment in some, but not all patients.",
"     </li>",
"     <li>",
"      Hypervitaminosis A from excessive dietary intake has been a long-known cause of IIH [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/36,46\">",
"       36,46",
"      </a>",
"      ]. Other retinoids used in the treatment of dermatologic conditions and cancer therapy, all-trans-retinoic acid, retinol,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      , etretinate, and tretinoin have also been reported to be associated with IIH [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/36,37,41,47-51\">",
"       36,37,41,47-51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More limited, possibly anecdotal evidence link other medications with IIH:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thyroid replacement [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/22,52-54\">",
"       22,52-54",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Corticosteroid withdrawal [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/27,55,56\">",
"       27,55,56",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/57-60\">",
"       57-60",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Nalidixic acid [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/23,61\">",
"       23,61",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"       Nitrofurantoin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/62,63\">",
"       62,63",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Systemic illnesses",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to obesity, systemic illnesses reportedly associated with IIH include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Addison disease [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/64,65\">",
"       64,65",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hypoparathyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/66\">",
"       66",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Anemia, usually severe [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/14,67-69\">",
"       14,67-69",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Sleep apnea [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/14,17,70,71\">",
"       14,17,70,71",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Systemic lupus erythematosus (SLE) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/72-74\">",
"       72-74",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Behcet's syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/75,76\">",
"       75,76",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Polycystic ovary syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/77\">",
"       77",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Coagulation disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/77-80\">",
"       77-80",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Uremia [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/81\">",
"       81",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathogenic mechanisms associating these conditions with IIH are uncertain and in some cases the apparent association may be indirect or spurious. As examples, polycystic ovary syndrome and sleep apnea are associated with obesity and therefore may be secondarily associated with IIH. In SLE, cases of apparent IIH may be due to occult cerebral venous thrombosis (related to inflammation of the venous sinus or hypercoagulability) or to corticosteroid withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/72\">",
"     72",
"    </a>",
"    ]. Other hypercoagulable syndromes, sarcoidosis, and Behcet's may also be associated with IIH by causing secondary intracranial hypertension via occult venous sinus thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=see_link&amp;anchor=H12#H12\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many theories for IIH have been proposed, the precise pathogenesis of IIH remains unknown. Any theory must account for the high incidence of IIH in obese women of the childbearing years. Proposed etiologies include cerebral venous outflow abnormalities (eg, venous stenoses and venous hypertension); increased cerebrospinal fluid (CSF) outflow resistance at either the level of the arachnoid granulations or CSF lymphatic drainage sites; obesity-related increased abdominal and intracranial venous pressure; altered sodium and water retention mechanisms; and abnormalities of vitamin A metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Intracranial venous hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated intracranial venous pressure is postulated both as a primary mechanism and as a \"final common pathway\" for IIH. This theory is supported by the similar clinical appearances of IIH and secondary intracranial hypertension due to cerebral venous thrombosis and other causes of obstructed venous outflow. Some patients thought to have IIH have been later discovered to have one of these conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/75,83-85\">",
"     75,83-85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=see_link&amp;anchor=H12#H12\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although several authors have reported cerebral venous outflow abnormalities on magnetic resonance imaging (MRI) and MR venography (MRV) in patients with IIH, there is some disagreement as to the frequency or the significance of these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/18,86,87\">",
"     18,86,87",
"    </a>",
"    ]. Clear venous sinus thrombosis has definite clinicopathologic significance, but apparent venous sinus narrowing or stenosis may not [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/88\">",
"     88",
"    </a>",
"    ]. Differentiation of venous stenosis from flow related abnormalities, especially on non-contrast MRV, can be difficult as flow-related artifacts can mimic venous sinus stenoses or even be mistaken for sinus thrombosis. These can sometimes be resolved with post-contrast MRV. Literature that suggests a high frequency of venous sinus abnormalities in patients with IIH must be viewed with caution.",
"   </p>",
"   <p>",
"    Cerebral venous sinus structural abnormalities were systematically identified in a series of 29 patients with IIH using a specialized MR venography technique, auto-triggered elliptic-centric-ordered three-dimensional gadolinium-enhanced MR venography (ATECO MRV) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/89\">",
"     89",
"    </a>",
"    ]. Blinded readers detected substantial bilateral sinovenous stenoses in 27 of 29 patients compared with 4 of 59 controls, corresponding to a sensitivity and specificity of 93 percent. The investigators speculated that congenital narrowing of the venous sinus might be a primary cause of IIH or instead may be a secondary, but potentially contributing factor. In the latter scenario, increased CSF pressure compresses the transverse sinus leading to the stenosis, which in turn would exacerbate the increased intracranial pressure (ICP), potentially bringing the patient to clinical presentation.",
"   </p>",
"   <p>",
"    There is other evidence to suggest that these apparent venous abnormalities are a secondary, not a primary or causative phenomenon. One study documented high intracranial venous sinus pressures in patients with IIH that was reduced by removal of CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/90\">",
"     90",
"    </a>",
"    ]. This finding implies that increased cerebral venous sinus pressure and apparent stenosis in IIH is caused by the elevated ICP and not the reverse. Other reports have also documented reversal of apparent transverse sinus stenosis after CSF shunting [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/91-96\">",
"     91-96",
"    </a>",
"    ]. In contrast, one case series documented persistent transverse sinus stenosis in nine patients with IIH whose CSF pressure normalized over six years with medical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other theories",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some evidence that central obesity increases intra-abdominal pressure, pleural pressure, cardiac filling pressure, and central venous pressure and may lead to increased intracranial venous pressure and IIH [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/98\">",
"     98",
"    </a>",
"    ]. Limited support for this theory comes from a report of seven obese women with IIH who reported subjective symptom relief with the use of an externally applied device that lowered abdominal pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/99\">",
"     99",
"    </a>",
"    ]. However, this mechanism does not account for the gender difference in IIH, the lack of increased incidence in pregnancy, and the cases of IIH in thin patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/100,101\">",
"     100,101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cerebral edema was one of the earliest proposed mechanisms for IIH and had pathologic support in one case series [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/102\">",
"     102",
"    </a>",
"    ]. However, subsequent pathologic and MRI studies have not found evidence of cerebral edema in patients with IIH [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/103-106\">",
"     103-106",
"    </a>",
"    ]. A link between IIH and altered sodium and water retention was suggested by another report in which 77 percent of IIH patients had evidence of peripheral edema and 80 percent had orthostatic retention of sodium and water [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/107\">",
"     107",
"    </a>",
"    ]. Impaired saline and water load excretions were noted in the upright posture in IIH patients with orthostatic edema compared to lean and obese controls without IIH. However, the precise mechanisms linking orthostatic changes and IIH were not defined, and many IIH patients do not have these sodium and water abnormalities.",
"   </p>",
"   <p>",
"    Reports of IIH occurring in association with vitamin A intoxication have suggested a role for vitamin A in the pathogenesis of IIH [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/36,46\">",
"     36,46",
"    </a>",
"    ]. Elevated serum vitamin A, retinol, and retinol binding protein levels have been reported in some, but not all IIH patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. In other studies, higher CSF vitamin A, retinol, and retinol binding protein levels have been found in IIH patients compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/110-112\">",
"     110-112",
"    </a>",
"    ]. The significance of these findings remains unknown. One theory suggests that excess retinol or retinol binding protein in the CSF interferes with CSF resorption.",
"   </p>",
"   <p>",
"    Other causes of impaired CSF absorption or increased CSF production have also been postulated as an etiology of IIH. As an example, one hypothesis proposes that microthrombosis in the sagittal sinus may block CSF absorption in the arachnoid granulations there even in the absence of a thrombosis of sufficient size to be seen on neuroimaging studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/77,113\">",
"     77,113",
"    </a>",
"    ]. However, most known causes of impaired CSF absorption (after subarachnoid hemorrhage or infectious meningitis) and CSF overproduction (choroid plexus papilloma) produce hydrocephalus, which is not seen in IIH [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sleep apnea can be a complication of obesity, and may play a role in IIH, perhaps in men in particular [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/17,115\">",
"     17,115",
"    </a>",
"    ]. Hypercarbia may produce elevated ICP through vasodilation. Papilledema, but rarely IIH, is common in patients with sleep apnea. One study found that 14 of 37 patients with IIH had a sleep disturbance, and of these, 13 had evidence of sleep apnea or upper airway resistance syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/71\">",
"     71",
"    </a>",
"    ]. In another report, a patient with IIH underwent ICP monitoring with pulse oximetry to reveal that apneic episodes were associated with marked elevations of ICP [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have looked at the pathophysiology of obesity and its complications as a basis for IIH. Leptin is a protein secreted by adipose cells, in proportion to total body fat content. Higher serum leptin levels were found in 15 obese IIH patients compared to 16 obese and 15 non-obese controls [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/117\">",
"     117",
"    </a>",
"    ]. The pathophysiologic consequences of this finding are not known. Other studies of other adipokines and the gastric hormone, ghrelin, have not consistently found an association of these with IIH [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/113,118\">",
"     113,118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Few studies have examined the potential role of sex hormones in IIH. In one study of eight men with IIH, two had abnormal estradiol levels, four had abnormal follicle stimulating and luteinizing hormone levels, and seven had low testosterone levels [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15769/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/51/38706?source=see_link\">",
"       \"Patient information: Idiopathic intracranial hypertension (pseudotumor cerebri) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic intracranial hypertension (IIH) is a disorder defined by clinical criteria that include symptoms and signs isolated to those produced by increased intracranial pressure (eg, headache, papilledema, vision loss), elevated intracranial pressure with normal cerebrospinal fluid composition, and no other cause of intracranial hypertension evident on neuroimaging or other evaluations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of IIH in the general population is 1 to 2 per 100,000, and is 2 to 20 times higher in the primary risk group: overweight women of childbearing years. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In prepubertal children, female gender and obesity do not appear to be risk factors for IIH. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A long list of medications have been reported to be associated with IIH. The evidence linking growth hormone treatment, retinoids, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      antibiotics is strongest; however, the mechanisms by which these might produce IIH is not known. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other than obesity, the association between other medical conditions and IIH is not proven. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Systemic illnesses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of IIH is unknown. Much attention has been placed on the association of IIH with venous sinus stenosis. However, most of the evidence at present suggests that apparent venous sinus narrowing is secondary to increased intracranial pressure and is not the primary cause in most cases. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Intracranial venous hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other theories include increased cerebrospinal fluid outflow resistance; obesity-related increased abdominal and intracranial venous pressure; altered sodium and water retention mechanisms; and abnormalities of vitamin A metabolism. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Other theories'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/1\">",
"      Friedman DI, Jacobson DM. Diagnostic criteria for idiopathic intracranial hypertension. Neurology 2002; 59:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/2\">",
"      Durcan FJ, Corbett JJ, Wall M. The incidence of pseudotumor cerebri. Population studies in Iowa and Louisiana. Arch Neurol 1988; 45:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/3\">",
"      Radhakrishnan K, Ahlskog JE, Cross SA, et al. Idiopathic intracranial hypertension (pseudotumor cerebri). Descriptive epidemiology in Rochester, Minn, 1976 to 1990. Arch Neurol 1993; 50:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/4\">",
"      Kesler A, Gadoth N. Epidemiology of idiopathic intracranial hypertension in Israel. J Neuroophthalmol 2001; 21:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/5\">",
"      Curry WT Jr, Butler WE, Barker FG 2nd. Rapidly rising incidence of cerebrospinal fluid shunting procedures for idiopathic intracranial hypertension in the United States, 1988-2002. Neurosurgery 2005; 57:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/6\">",
"      Corbett JJ, Savino PJ, Thompson HS, et al. Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol 1982; 39:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/7\">",
"      Ireland B, Corbett JJ, Wallace RB. The search for causes of idiopathic intracranial hypertension. A preliminary case-control study. Arch Neurol 1990; 47:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/8\">",
"      Jain N, Rosner F. Idiopathic intracranial hypertension: report of seven cases. Am J Med 1992; 93:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/9\">",
"      Wall M, George D. Idiopathic intracranial hypertension. A prospective study of 50 patients. Brain 1991; 114 ( Pt 1A):155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/10\">",
"      Giuseffi V, Wall M, Siegel PZ, Rojas PB. Symptoms and disease associations in idiopathic intracranial hypertension (pseudotumor cerebri): a case-control study. Neurology 1991; 41:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/11\">",
"      Kesler A, Goldhammer Y, Gadoth N. Do men with pseudomotor cerebri share the same characteristics as women? A retrospective review of 141 cases. J Neuroophthalmol 2001; 21:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/12\">",
"      Bruce BB, Preechawat P, Newman NJ, et al. Racial differences in idiopathic intracranial hypertension. Neurology 2008; 70:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/13\">",
"      Galvin JA, Van Stavern GP. Clinical characterization of idiopathic intracranial hypertension at the Detroit Medical Center. J Neurol Sci 2004; 223:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/14\">",
"      Bruce BB, Kedar S, Van Stavern GP, et al. Atypical idiopathic intracranial hypertension: normal BMI and older patients. Neurology 2010; 74:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/15\">",
"      Soler D, Cox T, Bullock P, et al. Diagnosis and management of benign intracranial hypertension. Arch Dis Child 1998; 78:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/16\">",
"      Digre KB, Corbett JJ. Pseudotumor cerebri in men. Arch Neurol 1988; 45:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/17\">",
"      Lee AG, Golnik K, Kardon R, et al. Sleep apnea and intracranial hypertension in men. Ophthalmology 2002; 109:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/18\">",
"      Johnston I, Kollar C, Dunkley S, et al. Cranial venous outflow obstruction in the pseudotumour syndrome: incidence, nature and relevance. J Clin Neurosci 2002; 9:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/19\">",
"      Balcer LJ, Liu GT, Forman S, et al. Idiopathic intracranial hypertension: relation of age and obesity in children. Neurology 1999; 52:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/20\">",
"      Cinciripini GS, Donahue S, Borchert MS. Idiopathic intracranial hypertension in prepubertal pediatric patients: characteristics, treatment, and outcome. Am J Ophthalmol 1999; 127:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/21\">",
"      Gordon K. Pediatric pseudotumor cerebri: descriptive epidemiology. Can J Neurol Sci 1997; 24:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/22\">",
"      Lessell S. Pediatric pseudotumor cerebri (idiopathic intracranial hypertension). Surv Ophthalmol 1992; 37:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/23\">",
"      Scott IU, Siatkowski RM, Eneyni M, et al. Idiopathic intracranial hypertension in children and adolescents. Am J Ophthalmol 1997; 124:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/24\">",
"      Genizi J, Lahat E, Zelnik N, et al. Childhood-onset idiopathic intracranial hypertension: relation of sex and obesity. Pediatr Neurol 2007; 36:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/25\">",
"      Warman R. Management of pseudotumor cerebri in children. Int Pediatr 2000; 15:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/26\">",
"      Distelmaier F, Sengler U, Messing-Juenger M, et al. Pseudotumor cerebri as an important differential diagnosis of papilledema in children. Brain Dev 2006; 28:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/27\">",
"      Bandyopadhyay S, Jacobson DM. Clinical features of late-onset pseudotumor cerebri fulfilling the modified dandy criteria. J Neuroophthalmol 2002; 22:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/28\">",
"      Blethen SL. Complications of growth hormone therapy in children. Curr Opin Pediatr 1995; 7:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/29\">",
"      Francois I, Casteels I, Silberstein J, et al. Empty sella, growth hormone deficiency and pseudotumour cerebri: effect of initiation, withdrawal and resumption of growth hormone therapy. Eur J Pediatr 1997; 156:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/30\">",
"      Koller EA, Stadel BV, Malozowski SN. Papilledema in 15 renally compromised patients treated with growth hormone. Pediatr Nephrol 1997; 11:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/31\">",
"      Malozowski S, Tanner LA, Wysowski DK, et al. Benign intracranial hypertension in children with growth hormone deficiency treated with growth hormone. J Pediatr 1995; 126:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/32\">",
"      Rogers AH, Rogers GL, Bremer DL, McGregor ML. Pseudotumor cerebri in children receiving recombinant human growth hormone. Ophthalmology 1999; 106:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/33\">",
"      Maneatis T, Baptista J, Connelly K, Blethen S. Growth hormone safety update from the National Cooperative Growth Study. J Pediatr Endocrinol Metab 2000; 13 Suppl 2:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/34\">",
"      Reeves GD, Doyle DA. Growth hormone treatment and pseudotumor cerebri: coincidence or close relationship? J Pediatr Endocrinol Metab 2002; 15 Suppl 2:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/35\">",
"      Vischi A, Guerriero S, Giancipoli G, et al. Delayed onset of pseudotumor cerebri syndrome 7 years after starting human recombinant growth hormone treatment. Eur J Ophthalmol 2006; 16:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/36\">",
"      Friedman DI. Medication-induced intracranial hypertension in dermatology. Am J Clin Dermatol 2005; 6:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/37\">",
"      Moskowitz Y, Leibowitz E, Ronen M, Aviel E. Pseudotumor cerebri induced by vitamin A combined with minocycline. Ann Ophthalmol 1993; 25:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/38\">",
"      Sirdofsky M, Kattah J, Macedo P. Intracranial hypertension in a dieting patient. J Neuroophthalmol 1994; 14:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/39\">",
"      Ang ER, Zimmerman JC, Malkin E. Pseudotumor cerebri secondary to minocycline intake. J Am Board Fam Pract 2002; 15:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/40\">",
"      Chiu AM, Chuenkongkaew WL, Cornblath WT, et al. Minocycline treatment and pseudotumor cerebri syndrome. Am J Ophthalmol 1998; 126:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/41\">",
"      Friedman DI, Gordon LK, Egan RA, et al. Doxycycline and intracranial hypertension. Neurology 2004; 62:2297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/42\">",
"      Gardner K, Cox T, Digre KB. Idiopathic intracranial hypertension associated with tetracycline use in fraternal twins: case reports and review. Neurology 1995; 45:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/43\">",
"      Kesler A, Goldhammer Y, Hadayer A, Pianka P. The outcome of pseudotumor cerebri induced by tetracycline therapy. Acta Neurol Scand 2004; 110:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/44\">",
"      Mochizuki K, Takahashi T, Kano M, et al. Pseudotumor cerebri induced by minocycline therapy for acne vulgaris. Jpn J Ophthalmol 2002; 46:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/45\">",
"      Fraser CL, Biousse V, Newman NJ. Minocycline-induced fulminant intracranial hypertension. Arch Neurol 2012; 69:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/46\">",
"      Donahue SP. Recurrence of idiopathic intracranial hypertension after weight loss: the carrot craver. Am J Ophthalmol 2000; 130:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/47\">",
"      Alemayehu W. Pseudotumor cerebri (toxic effect of the \"magic bullet\"). Ethiop Med J 1995; 33:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/48\">",
"      Sharieff GQ, Hanten K. Pseudotumor cerebri and hypercalcemia resulting from vitamin A toxicity. Ann Emerg Med 1996; 27:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/49\">",
"      Colucciello M. Pseudotumor cerebri induced by all-trans retinoic acid treatment of acute promyelocytic leukemia. Arch Ophthalmol 2003; 121:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/50\">",
"      Yeh YC, Tang HF, Fang IM. Pseudotumor cerebri caused by all-trans-retinoic acid treatment for acute promyelocytic leukemia. Jpn J Ophthalmol 2006; 50:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/51\">",
"      Fraunfelder FW, Fraunfelder FT, Corbett JJ. Isotretinoin-associated intracranial hypertension. Ophthalmology 2004; 111:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/52\">",
"      Serratrice J, Granel B, Conrath J, et al. Benign intracranial hypertension and thyreostimulin suppression hormonotherapy. Am J Ophthalmol 2002; 134:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/53\">",
"      Campos SP, Olitsky S. Idiopathic intracranial hypertension after L-thyroxine therapy for acquired primary hypothyroidism. Clin Pediatr (Phila) 1995; 34:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/54\">",
"      Raghavan S, DiMartino-Nardi J, Saenger P, Linder B. Pseudotumor cerebri in an infant after L-thyroxine therapy for transient neonatal hypothyroidism. J Pediatr 1997; 130:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/55\">",
"      Liu GT, Kay MD, Bienfang DC, Schatz NJ. Pseudotumor cerebri associated with corticosteroid withdrawal in inflammatory bowel disease. Am J Ophthalmol 1994; 117:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/56\">",
"      Rickels MR, Nichols CW. Pseudotumor cerebri in patients with Cushing's disease. Endocr Pract 2004; 10:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/57\">",
"      Ames D, Wirshing WC, Cokely HT, Lo LL. The natural course of pseudotumor cerebri in lithium-treated patients. J Clin Psychopharmacol 1994; 14:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/58\">",
"      Dommisse J. Pseudotumor cerebri associated with lithium therapy in two patients. J Clin Psychiatry 1991; 52:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/59\">",
"      Hexom B, Barthel RP. Lithium and pseudotumor cerebri. J Am Acad Child Adolesc Psychiatry 2004; 43:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/60\">",
"      Levine SH, Puchalski C. Pseudotumor cerebri associated with lithium therapy in two patients. J Clin Psychiatry 1990; 51:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/61\">",
"      Mukherjee A, Dutta P, Lahiri M, et al. Benign intracranial hypertension after nalidixic acid overdose in infants. Lancet 1990; 335:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/62\">",
"      Mushet GR. Pseudotumor and nitrofurantoin therapy. Arch Neurol 1977; 34:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/63\">",
"      Francis PJ, Haywood S, Rigden S, et al. Benign intracranial hypertension in children following renal transplantation. Pediatr Nephrol 2003; 18:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/64\">",
"      Condulis N, Germain G, Charest N, et al. Pseudotumor cerebri: a presenting manifestation of Addison's disease. Clin Pediatr (Phila) 1997; 36:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/65\">",
"      Alexandrakis G, Filatov V, Walsh T. Pseudotumor cerebri in a 12-year-old boy with Addison's disease. Am J Ophthalmol 1993; 116:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/66\">",
"      Sheldon RS, Becker WJ, Hanley DA, Culver RL. Hypoparathyroidism and pseudotumor cerebri: an infrequent clinical association. Can J Neurol Sci 1987; 14:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/67\">",
"      Biousse V, Rucker JC, Vignal C, et al. Anemia and papilledema. Am J Ophthalmol 2003; 135:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/68\">",
"      Segal L, Discepola M. Idiopathic intracranial hypertension and sickle cell disease: two case reports. Can J Ophthalmol 2005; 40:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/69\">",
"      Nazir SA, Siatkowski RM. Pseudotumor cerebri in idiopathic aplastic anemia. J AAPOS 2003; 7:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/70\">",
"      Purvin VA, Kawasaki A, Yee RD. Papilledema and obstructive sleep apnea syndrome. Arch Ophthalmol 2000; 118:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/71\">",
"      Marcus DM, Lynn J, Miller JJ, et al. Sleep disorders: a risk factor for pseudotumor cerebri? J Neuroophthalmol 2001; 21:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/72\">",
"      Dave S, Longmuir R, Shah VA, et al. Intracranial hypertension in systemic lupus erythematosus. Semin Ophthalmol 2008; 23:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/73\">",
"      Hershko AY, Berkun Y, Mevorach D, et al. Increased intracranial pressure related to systemic lupus erythematosus: a 26-year experience. Semin Arthritis Rheum 2008; 38:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/74\">",
"      Green L, Vinker S, Amital H, et al. Pseudotumor cerebri in systemic lupus erythematosus. Semin Arthritis Rheum 1995; 25:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/75\">",
"      Celebisoy N, Se&ccedil;il Y, Aky&uuml;rekli O. Pseudotumor cerebri: etiological factors, presenting features and prognosis in the western part of Turkey. Acta Neurol Scand 2002; 106:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/76\">",
"      Palacio E, Rodero L, Pascual J. Topiramate-responsive headache due to idiopathic intracranial hypertension in Beh&ccedil;et syndrome. Headache 2004; 44:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/77\">",
"      Glueck CJ, Iyengar S, Goldenberg N, et al. Idiopathic intracranial hypertension: associations with coagulation disorders and polycystic-ovary syndrome. J Lab Clin Med 2003; 142:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/78\">",
"      Kesler A, Ellis MH, Reshef T, et al. Idiopathic intracranial hypertension and anticardiolipin antibodies. J Neurol Neurosurg Psychiatry 2000; 68:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/79\">",
"      Leker RR, Steiner I. Anticardiolipin antibodies are frequently present in patients with idiopathic intracranial hypertension. Arch Neurol 1998; 55:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/80\">",
"      Sussman J, Leach M, Greaves M, et al. Potentially prothrombotic abnormalities of coagulation in benign intracranial hypertension. J Neurol Neurosurg Psychiatry 1997; 62:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/81\">",
"      Chang D, Nagamoto G, Smith WE. Benign intracranial hypertension and chronic renal failure. Cleve Clin J Med 1992; 59:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/82\">",
"      Biousse V, Bruce BB, Newman NJ. Update on the pathophysiology and management of idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry 2012; 83:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/83\">",
"      Biousse V, Ameri A, Bousser MG. Isolated intracranial hypertension as the only sign of cerebral venous thrombosis. Neurology 1999; 53:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/84\">",
"      Lin A, Foroozan R, Danesh-Meyer HV, et al. Occurrence of cerebral venous sinus thrombosis in patients with presumed idiopathic intracranial hypertension. Ophthalmology 2006; 113:2281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/85\">",
"      Tehindrazanarivelo A, Evrard S, Schaison M, et al. Prospective study of cerebral sinus venous thrombosis in patients presenting with benign intracranial hypertension. Cerebrovasc Dis 1992; 2:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/86\">",
"      Lee AG, Brazis PW. Magnetic resonance venography in idiopathic pseudotumor cerebri. J Neuroophthalmol 2000; 20:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/87\">",
"      Higgins JN, Tipper G, Varley M, Pickard JD. Transverse sinus stenoses in benign intracranial hypertension demonstrated on CT venography. Br J Neurosurg 2005; 19:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/88\">",
"      Bono F, Lupo MR, Lavano A, et al. Cerebral MR venography of transverse sinuses in subjects with normal CSF pressure. Neurology 2003; 61:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/89\">",
"      Farb RI, Vanek I, Scott JN, et al. Idiopathic intracranial hypertension: the prevalence and morphology of sinovenous stenosis. Neurology 2003; 60:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/90\">",
"      King JO, Mitchell PJ, Thomson KR, Tress BM. Manometry combined with cervical puncture in idiopathic intracranial hypertension. Neurology 2002; 58:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/91\">",
"      Simister R, Bowler JV, Wilson PL, et al. Transverse venous sinus stenosis and intracranial hypertension: evidence for which comes first. J Neurol 2008; 255:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/92\">",
"      McGonigal A, Bone I, Teasdale E. Resolution of transverse sinus stenosis in idiopathic intracranial hypertension after L-P shunt. Neurology 2004; 62:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/93\">",
"      Higgins JN, Pickard JD. Lateral sinus stenoses in idiopathic intracranial hypertension resolving after CSF diversion. Neurology 2004; 62:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/94\">",
"      Rohr A, D&ouml;rner L, Stingele R, et al. Reversibility of venous sinus obstruction in idiopathic intracranial hypertension. AJNR Am J Neuroradiol 2007; 28:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/95\">",
"      De Simone R, Marano E, Fiorillo C, et al. Sudden re-opening of collapsed transverse sinuses and longstanding clinical remission after a single lumbar puncture in a case of idiopathic intracranial hypertension. Pathogenetic implications. Neurol Sci 2005; 25:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/96\">",
"      Baryshnik DB, Farb RI. Changes in the appearance of venous sinuses after treatment of disordered intracranial pressure. Neurology 2004; 62:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/97\">",
"      Bono F, Giliberto C, Mastrandrea C, et al. Transverse sinus stenoses persist after normalization of the CSF pressure in IIH. Neurology 2005; 65:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/98\">",
"      Sugerman HJ, DeMaria EJ, Felton WL 3rd, et al. Increased intra-abdominal pressure and cardiac filling pressures in obesity-associated pseudotumor cerebri. Neurology 1997; 49:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/99\">",
"      Sugerman HJ, Felton III WL 3rd, Sismanis A, et al. Continuous negative abdominal pressure device to treat pseudotumor cerebri. Int J Obes Relat Metab Disord 2001; 25:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/100\">",
"      Friedman DI. Cerebral venous pressure, intra-abdominal pressure, and dural venous sinus stenting in idiopathic intracranial hypertension. J Neuroophthalmol 2006; 26:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/101\">",
"      Digre KB, Varner MW, Corbett JJ. Pseudotumor cerebri and pregnancy. Neurology 1984; 34:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/102\">",
"      Sahs, AL, Joynt, RJ. Brain swelling of unknown cause. Neurology 1954; 6:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/103\">",
"      Wall M, Dollar JD, Sadun AA, Kardon R. Idiopathic intracranial hypertension. Lack of histologic evidence for cerebral edema. Arch Neurol 1995; 52:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/104\">",
"      Bastin ME, Sinha S, Farrall AJ, et al. Diffuse brain oedema in idiopathic intracranial hypertension: a quantitative magnetic resonance imaging study. J Neurol Neurosurg Psychiatry 2003; 74:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/105\">",
"      Bicakci K, Bicakci S, Aksungur E. Perfusion and diffusion magnetic resonance imaging in idiopathic intracranial hypertension. Acta Neurol Scand 2006; 114:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/106\">",
"      Owler BK, Higgins JN, P&eacute;na A, et al. Diffusion tensor imaging of benign intracranial hypertension: absence of cerebral oedema. Br J Neurosurg 2006; 20:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/107\">",
"      Friedman DI, Streeten DH. Idiopathic intracranial hypertension and orthostatic edema may share a common pathogenesis. Neurology 1998; 50:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/108\">",
"      Jacobson DM, Berg R, Wall M, et al. Serum vitamin A concentration is elevated in idiopathic intracranial hypertension. Neurology 1999; 53:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/109\">",
"      Selhorst JB, Kulkantrakorn K, Corbett JJ, et al. Retinol-binding protein in idiopathic intracranial hypertension (IIH). J Neuroophthalmol 2000; 20:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/110\">",
"      Warner JE, Bernstein PS, Yemelyanov A, et al. Vitamin A in the cerebrospinal fluid of patients with and without idiopathic intracranial hypertension. Ann Neurol 2002; 52:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/111\">",
"      Tabassi A, Salmasi AH, Jalali M. Serum and CSF vitamin A concentrations in idiopathic intracranial hypertension. Neurology 2005; 64:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/112\">",
"      Warner JE, Larson AJ, Bhosale P, et al. Retinol-binding protein and retinol analysis in cerebrospinal fluid and serum of patients with and without idiopathic intracranial hypertension. J Neuroophthalmol 2007; 27:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/113\">",
"      Ooi LY, Walker BR, Bodkin PA, Whittle IR. Idiopathic intracranial hypertension: can studies of obesity provide the key to understanding pathogenesis? Br J Neurosurg 2008; 22:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/114\">",
"      Skau M, Brennum J, Gjerris F, Jensen R. What is new about idiopathic intracranial hypertension? An updated review of mechanism and treatment. Cephalalgia 2006; 26:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/115\">",
"      Bruce BB, Kedar S, Van Stavern GP, et al. Idiopathic intracranial hypertension in men. Neurology 2009; 72:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/116\">",
"      Burgett RA, Purvin VA, Kawasaki A. Lumboperitoneal shunting for pseudotumor cerebri. Neurology 1997; 49:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/117\">",
"      Lampl Y, Eshel Y, Kessler A, et al. Serum leptin level in women with idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry 2002; 72:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15769/abstract/118\">",
"      Subramanian PS, Goldenberg-Cohen N, Shukla S, et al. Plasma ghrelin levels are normal in obese patients with idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol 2004; 138:109.",
"     </a>",
"    </li>",
"    <li>",
"     Lee, A, Kardon, R, Wall, M, Schlechte, J. Endocrinologic abnormalities in pseudotumor cerebri in men. In: 28th Annual North American Neuro-Ophthalmology Society Meeting, Copper Mountain, CO 2002.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5254 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-17F8E0A872-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_25_15769=[""].join("\n");
var outline_f15_25_15769=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Associated conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Systemic illnesses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Intracranial venous hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other theories",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/54/41833?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/51/38706?source=related_link\">",
"      Patient information: Idiopathic intracranial hypertension (pseudotumor cerebri) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=related_link\">",
"      Treatment of growth hormone deficiency in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_25_15770="Model for End-stage Liver Disease (MELD)";
var content_f15_25_15770=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Model for End-stage Liver Disease (MELD)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/25/15770/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/25/15770/contributors\">",
"     Kiran Bambha, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/25/15770/contributors\">",
"     Patrick S Kamath, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/25/15770/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/25/15770/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/25/15770/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/25/15770/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/25/15770/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prognostic models are useful in estimating disease severity and survival and are used to make decisions regarding specific medical interventions. These models are developed using analytical methods that involve determining the effects of variables of interest (eg, demographic data, clinical data and laboratory values) on specific outcomes such as death.",
"   </p>",
"   <p>",
"    Several prognostic models are currently used in healthcare settings. Some focus on generalized health status, such as the Acute Physiology and Chronic Health Evaluation System (APACHE III) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/1\">",
"     1",
"    </a>",
"    ], while others are disease specific. Examples of the latter include models for predicting survival in patients with primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and alcoholic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Two models that are used commonly in the care of patients with chronic liver disease are the Child-Pugh score and the more recently described Model for End-stage Liver Disease (MELD) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/6-10\">",
"     6-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MELD OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;MELD is a prospectively developed and validated chronic liver disease severity scoring system that uses a patient's laboratory values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?21/23/21874?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?18/2/18466?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). In patients with chronic liver disease, an increasing MELD score is associated with increasing severity of hepatic dysfunction and three-month mortality risk [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/11\">",
"     11",
"    </a>",
"    ]. Given its accuracy in predicting short-term survival among patients with end-stage liver disease, MELD has been adopted by the transplant community in the United States for prioritization of patients awaiting liver transplantation. As will be discussed below, the MELD score has been modified slightly since its original development such that the etiology of liver disease is no longer routinely included in the model. Furthermore, revisions to the MELD scoring system have eliminated the possibility of generating negative scores.",
"   </p>",
"   <p>",
"    The MELD model that is currently used by the United Network for Organ Sharing (UNOS) in prioritizing allocation of deceased donor organs for liver transplantation is calculated according to the following formula:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MELD = 3.8[Ln serum bilirubin",
"      <span class=\"nowrap\">",
"       (mg/dL)]",
"      </span>",
"      + 11.2[Ln INR] + 9.6[Ln serum creatinine",
"      <span class=\"nowrap\">",
"       (mg/dL)]",
"      </span>",
"      + 6.4",
"      <br/>",
"      <br/>",
"      where Ln is the natural logarithm. For ease of use, several calculators are readily available for calculating the MELD score (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?21/23/21874?source=see_link\">",
"       calculator 1",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?18/2/18466?source=see_link\">",
"       calculator 2",
"      </a>",
"      ) (",
"      <a class=\"external\" href=\"file://optn.transplant.hrsa.gov/resources/professionalResources.asp?index=8\">",
"       file://optn.transplant.hrsa.gov/resources/professionalResources.asp?index=8",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEVELOPMENT OF MELD IN PATIENTS WITH CHRONIC LIVER DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;MELD was developed initially using data from a population of 231 patients with cirrhosis seen at four medical centers in the United States who underwent elective transjugular intrahepatic portosystemic shunt (TIPS) procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/8\">",
"     8",
"    </a>",
"    ]. Of these patients, 110 died during follow-up, with 70 of these deaths occurring within three months after the procedure. The MELD scoring system was developed from these data using Cox proportional hazards regression modeling to identify patients whose predicted survival post-procedure would be three months or less.",
"   </p>",
"   <p>",
"    Serum bilirubin, serum creatinine, INR and liver disease etiology (classified as alcoholic, cholestatic, viral hepatitis, and \"other\") were strong predictors of three-month survival. The formula used for calculation of the MELD score in this study was:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      3.8[Ln serum bilirubin",
"      <span class=\"nowrap\">",
"       (mg/dL)]",
"      </span>",
"      + 11.2[Ln INR] + 9.6[Ln serum creatinine",
"      <span class=\"nowrap\">",
"       (mg/dL)]",
"      </span>",
"      + 6.4[etiology: 0 if cholestatic or alcoholic, 1 if other etiologies]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with cirrhosis secondary to either alcoholic or cholestatic liver disease demonstrated slightly better survival compared with patients with viral or \"other\" disease etiologies. As a result, the MELD score was initially designed to reflect this mortality difference. Thus, even when the serum bilirubin, creatinine, and INR were identical, patients with cirrhosis due to nonalcoholic and noncholestatic liver disease generated a higher MELD score compared with patients with cholestatic and alcoholic liver disease. This model was validated in an independent population of patients from the Netherlands who underwent TIPS placement [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since survival following TIPS is primarily determined by the severity of the underlying liver disease, and since MELD is an accurate predictor of survival after TIPS, it was hypothesized that the MELD score might be useful as a prognostic indicator in patients with a broader range of liver disease severity and etiology. The first study to address this question was conducted in diverse populations of patients with cirrhosis who did not have TIPS placed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/9\">",
"     9",
"    </a>",
"    ]. Four independent patient populations (total n = 2278) were studied including (1) hospitalized patients with hepatic decompensation; (2) ambulatory patients with non-cholestatic liver disease; (3) patients with PBC; and (4) a historical cohort of unselected patients with cirrhosis seen at Mayo Clinic Rochester at a time when liver transplantation was not available. Patients with hepatocellular carcinoma (HCC), recent alcohol use, intrinsic renal disease, sepsis, and those patients admitted for liver transplantation were excluded from the study.",
"   </p>",
"   <p>",
"    The MELD score was an accurate predictor of three-month survival in all four patient populations, with concordance (c)&ndash;statistics of 0.87 for hospitalized patients, 0.80 for ambulatory non-cholestatic liver disease, 0.87 for PBC, and 0.78 for the historical cohort of cirrhotic patients. The c-statistic is equivalent to the area under the receiver operating characteristic curve and tests the probability that, among randomly selected patients, the patient with a greater risk score is more likely to die within a three-month period compared with a patient with a lower risk score. In this context, a c-statistic may range from 0 to 1, with 1 corresponding to a perfect test with 100 percent accuracy and 0.5 corresponding to a clinically useless test that is accurate only 50 percent of the time. A c-statistic greater than 0.7 generally indicates a clinically useful test, and a c-statistic greater than 0.8 indicates excellent accuracy. A c-statistic of 0.8, for example, indicates that 8 out of 10 times a patient with a higher MELD score is more likely to die within three months compared with a patient with a lower MELD score.",
"   </p>",
"   <p>",
"    As alluded to above, the inclusion of liver disease etiology into the MELD score posed some difficulties when it was first developed, such as how to categorize patients with multiple causes of liver disease. Modification of the MELD score by excluding etiology did not significantly affect the model's accuracy in predicting three-month survival [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/13\">",
"     13",
"    </a>",
"    ]. The modified MELD score was a slightly better predictor of three-month mortality in hospitalized patients compared with the Child-Pugh score and liver biochemical tests.",
"   </p>",
"   <p>",
"    Additionally, it has been shown that the inclusion of complications of portal hypertension (eg, ascites, encephalopathy, variceal bleeding and spontaneous bacterial peritonitis) in the MELD score does not substantially improve its predictive accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/9\">",
"     9",
"    </a>",
"    ]. This does not mean to imply that these complications are not associated with decreased survival, but rather that these complications are more likely to be associated with advanced liver disease as determined by the MELD score.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     COMPARISON OF MELD AND CHILD-PUGH SCORING SYSTEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the best known and widely published scoring systems of liver disease severity is the Child-Pugh system (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?27/26/28065?source=see_link\">",
"     calculator 3",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?28/28/29121?source=see_link\">",
"     calculator 4",
"    </a>",
"    ). It was initially developed by Child and Turcotte in 1964 to risk stratify patients undergoing shunt surgery for portal decompression [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/6\">",
"     6",
"    </a>",
"    ]. The original Child-Turcotte classification system, which was empirically derived and incorporated serum albumin, serum bilirubin, \"nutritional status\", ascites, and encephalopathy (",
"    <a class=\"graphic graphic_table graphicRef56436 \" href=\"UTD.htm?13/0/13323\">",
"     table 1",
"    </a>",
"    ), was criticized due to the ambiguity of some of its parameters.",
"   </p>",
"   <p>",
"    As a result, the Child-Turcotte system was modified by Pugh in 1972 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/7\">",
"     7",
"    </a>",
"    ]. Points were assigned to each element such that an overall score could be calculated. Furthermore, \"nutritional status\" was replaced by prolongation in prothrombin time, expressed in seconds. Thus, the original Child-Turcotte scoring system modified by Pugh is now commonly referred to as the Child-Pugh score, or more accurately, as the Child-Turcotte-Pugh (CTP) score.",
"   </p>",
"   <p>",
"    The current CTP scoring system is based upon five parameters: serum bilirubin, serum albumin, prothrombin time, ascites and encephalopathy. The sum of the points for each of these five parameters gives the total score and patients with chronic liver disease are placed into one of three CTP classes (A, B or C) (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"UTD.htm?8/21/8540\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although the CTP scoring system was derived empirically, it has proven to be a good predictor of outcome in patients with complications of portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/14\">",
"     14",
"    </a>",
"    ]. Because of the simplicity in its calculation, the CTP score has been the traditional scale used by many clinicians for assessing the risk of mortality in patients with cirrhosis.",
"   </p>",
"   <p>",
"    However, the CTP classification has some limitations. It is based upon subjective parameters such as the degree of ascites and encephalopathy. The quantification of the degree of abnormality in these two physical findings may vary among observers and the methods of detection and be altered substantially by medical interventions (eg, the use of diuretics for ascites, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"     rifaximin",
"    </a>",
"    for encephalopathy). As an example, the CTP score was developed before ultrasound quantification of ascites was routinely available. Ultrasound permits detection of minor degrees of ascites that might not have been detected on physical examination. Similarly, the clinical assessment of hepatic encephalopathy can be highly subjective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34153?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hepatic encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The CTP score is also limited in its discriminatory capacity due to both a \"ceiling\" and a \"floor\" effect. A patient with a serum bilirubin level of 4",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    for example, is assigned the same number of points as a patient with a bilirubin of 30",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    even though the degree of elevation in serum bilirubin level is known to be an important prognostic indicator in patients with chronic liver disease. Furthermore, two patients with serum albumin levels of 2.8 and 1.5",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    respectively (a difference that is potentially clinically important), would be assigned the same number of CTP points. Ultimately, based upon the CTP score, patients are categorized into one of only three CTP classes (A, B or C), thus it is not possible to distinguish liver disease severity further among patients within a single class.",
"   </p>",
"   <p>",
"    Additional issues that should be considered with respect to the CTP scoring system are the use of the prothrombin time and the use of serum albumin levels. Laboratories vary with regard to the sensitivity of the thromboplastin reagents used for measuring prothrombin time. Similarly, the normal values for serum albumin may also differ across different medical centers. Indeed, there may be enough laboratory-induced variation in the prothrombin time and serum albumin levels such that significant point changes may occur in the CTP score [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The limitations of the CTP score are of great significance in clinical practice, particularly in the context of stratifying and prioritizing patients for liver transplantation from different medical centers according to their calculated mortality risk. Thus, a desirable disease severity scoring system that will have broad practical utility should have the following characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rely on a few, readily available, objective variables",
"     </li>",
"     <li>",
"      Have general applicability to a heterogeneous group of patients with chronic liver disease",
"     </li>",
"     <li>",
"      Be able to distinguish disease severity along a broad continuum",
"     </li>",
"     <li>",
"      Be validated in diverse subsets of patients with chronic liver disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The MELD score meets all of these criteria. It is based upon three laboratory parameters (serum bilirubin, serum creatinine, and INR for prothrombin time), which are easily and reliably measured in almost all medical laboratories. Furthermore, rather than lumping ranges of laboratory abnormalities into groups, the MELD formula uses the exact laboratory values for serum bilirubin, creatinine, and INR, which permits the calculation of a highly discriminatory, continuous scoring system.",
"   </p>",
"   <p>",
"    However, the MELD score, like the CTP score, is vulnerable to variations in laboratory measurements. For example, despite being normalized for the sensitivity of thromboplastin, the INR can vary across laboratories if thromboplastin derived from rabbit brain is used rather than recombinant thromboplastin, potentially leading to important differences in prioritization of patients according to MELD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24022?source=see_link\">",
"     \"Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The MELD score may also be influenced by the method by which serum creatinine is measured. Variability in serum creatinine measurement using different assays is particularly problematic in the presence of an elevated serum bilirubin concentration, although this can be circumvented by using an enzymatic method to measure serum creatinine, particularly when the total bilirubin level is &gt;25",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The MELD score, which was developed in patients with chronic liver disease undergoing elective TIPS, has subsequently been validated as an accurate survival predictor in other subsets of patients with chronic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/21\">",
"     21",
"    </a>",
"    ]. Studies comparing the accuracy of MELD to the CTP score for predicting survival of patients on the liver transplant waiting list have generally demonstrated at least an equivalence, if not superiority, in the accuracy of the MELD score compared with the CTP score [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/22\">",
"     22",
"    </a>",
"    ]. The objective criteria used in the MELD score have led to widespread adoption of MELD as an accurate mortality predictor in patients awaiting liver transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     USE OF MELD FOR SELECTING PATIENTS FOR TIPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the MELD score was developed initially to predict survival among patients undergoing TIPS [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/8\">",
"     8",
"    </a>",
"    ]. The value of the MELD score in guiding medical decision making for TIPS is illustrated by the following examples. A patient with hepatitis C-induced cirrhosis with a creatinine of 1.0",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    bilirubin of 1.1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and an INR of 1.2 has a calculated MELD score of 9. The risk of mortality at three months is approximately 33 percent if this patient undergoes elective TIPS. In contrast, a patient with alcoholic liver disease who has a creatinine of 2.3",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    bilirubin of 17.4",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and an INR of 3.4 has a calculated MELD score of 39, which is associated with a three-month mortality risk of 94 percent post-TIPS.",
"   </p>",
"   <p>",
"    When using the original MELD score formula (which includes liver disease etiology), patients with a MELD score of less than eight generally do well after TIPS, while those with a score greater than 18 have a poorer outcome. Using the MELD score as modified by UNOS, the best outcomes occur among patients with a MELD score less than 14.",
"   </p>",
"   <p>",
"    As a general rule, TIPS should be avoided if possible in patients with a MELD score greater than 24, unless the procedure is being used as salvage therapy to control active variceal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Clinical judgment and extensive discussion with the patient, family members, and interventional radiology regarding the risks of hepatic decompensation are required in deciding whether to carry out TIPS in patients with MELD scores between 15 and 24. Patients with MELD scores greater than 24 who are reasonable liver transplant candidates are probably best served by foregoing the TIPS and waiting for liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the projected waiting time for a donor liver to become available can be long. As a result, there may be need to intervene to control complications from portal hypertension in patients with high MELD scores. Such patients should ideally be evaluated for liver transplantation before TIPS in case they develop irreversible hepatic decompensation after the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ADOPTION OF MELD FOR DECEASED DONOR LIVER ALLOCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 1990s, as the number of patients listed for liver transplantation increased and the number of available deceased donor livers remained stable, the number of patients dying while awaiting transplantation rose linearly. The time spent on the waiting list became an important, though undesirable, deciding factor in the allocation process. It was demonstrated that time spent on the liver transplant waiting list did not correlate with the risk of death while awaiting transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/26\">",
"     26",
"    </a>",
"    ]. Because of increasing concerns regarding this disparity in liver allocation, the Department of Health and Human Services issued a mandate in 1998 that deceased donor livers for transplantation be prioritized in a more equitable manner with a de-emphasis on time spent on the waiting list [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In response to this mandate, UNOS initially adopted the CTP scoring system for its liver transplantation prioritization system. However, it soon became apparent that the CTP score was not sufficient to resolve the dominance of waiting time as a deciding factor.",
"   </p>",
"   <p>",
"    The failure of the CTP score was due to several factors. First, the allocation system adopted by UNOS defined only three categories of disease severity in patients with chronic liver disease (status 2A, 2B, and 3), with the minimal listing criteria for liver transplantation being a CTP score of at least 7. Patients with a CTP score of 7 to 9 were placed in status 3, while those with a CTP score of at least 10 were status 2B. Patients deemed to be at risk of dying within seven days were made status 2A.",
"   </p>",
"   <p>",
"    This allocation system was thus limited in its ability to discriminate among patients with regard to disease severity as each category contained numerous patients and therefore waiting time continued to be a major, albeit unintended, factor in the allocation process. Furthermore, determining whether a patient would die within seven days was not based upon any validated criteria.",
"   </p>",
"   <p>",
"    During the liver transplantation community's search for a more equitable allocation system, the MELD score emerged as an ideal candidate for prioritizing patients based upon liver disease severity. An illustrative study included 3437 adult patients who were listed for liver transplantation between 1999 and 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/29\">",
"     29",
"    </a>",
"    ]. Of these, 412 died during the three-month follow-up period. Waiting list mortality was directly proportional to the MELD score at the time of listing, with mortality being 1.9 percent for patients with MELD scores less than 9, and 71 percent for patients with MELD scores &ge;40. The c-statistic for MELD's accuracy in predicting three-month mortality on the liver transplant waiting list was 0.83, compared with a c-statistic of 0.76 for the CTP score. Thus, in February 2002, MELD was adopted by UNOS as the basis for deceased donor liver allocation for adult (&ge;18 years) patients. MELD has now been adopted, or is under consideration for being adopted, by multiple countries and regions worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The original MELD score was a continuous numbering system with scores ranging from negative values to positive infinity. In practice, most patients have a score between 0 and 60. Because a negative score might create confusion in the minds of patients and their families (a negative score, in fact, indicates that the patient has a better survival than the rest of the cohort), UNOS modified the MELD scoring system to eliminate negative values by setting to 1.0 any measured laboratory values that were less than 1.0. Thus, patients with the combination of an INR of &le;1, serum creatinine &le;1",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and serum bilirubin &le;1",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    will receive the minimum score of 6 MELD points. In an effort to avoid an unfair advantage for patients with intrinsic renal disease, the maximum serum creatinine level was set to 4.0",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    which is also the value that is automatically assigned to patients on dialysis.",
"   </p>",
"   <p>",
"    The upper limit of the MELD score, as used by UNOS for liver allocation, is capped at 40 points. Thus, MELD scores for prioritization for liver transplant allocation may range from 6 to 40 points, with higher MELD scores connoting increasing severity of liver disease and increasing mortality risk. As an example, a patient awaiting liver transplantation with a MELD score &le;15 points has a predicted three-month survival of approximately 95 percent, while a patient with a MELD score of 30 points has a predicted three-month survival of approximately 65 percent. Patients with MELD scores of 40 points have a predicted three-month survival of only 10 to 15 percent (",
"    <a class=\"graphic graphic_figure graphicRef77732 \" href=\"UTD.htm?13/63/14333\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition to its utility in predicting three-month mortality among patients with end-stage liver disease awaiting liver transplantation, the MELD score has also been examined with respect to making an assessment of the survival benefit of liver transplantation. In a study of 1130 patients, a survival benefit at one-year post-liver transplant was demonstrated once a patient's MELD score reached 15 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/31\">",
"     31",
"    </a>",
"    ]. Stratifying by MELD score, the survival rates on the waiting list versus one-year post-liver transplant survival were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      MELD 10: 90 percent waiting list survival versus 83 percent 1-year post-liver transplant survival (p&lt;0.05)",
"     </li>",
"     <li>",
"      MELD 15: 81 versus 80 percent, respectively (p = 0.70)",
"     </li>",
"     <li>",
"      MELD 20: 63 versus 78 percent, respectively (p&lt;0.05)",
"     </li>",
"     <li>",
"      MELD 25: 42 versus 74 percent, respectively (p&lt;0.05)",
"     </li>",
"     <li>",
"      MELD 30: 21 versus 71 percent, respectively (p&lt;0.05)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once a patient has been deemed to be an acceptable candidate for liver transplantation by a transplant center, the patient's MELD score is used to determine that individual's immediate need for transplantation and patients are then ranked according to their MELD score and stratified by blood type. Patients have their MELD scores updated and forwarded regularly to UNOS by the listing transplant center according to UNOS directives [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/32\">",
"     32",
"    </a>",
"    ]. As a general rule, patients who are most severely ill will have their MELD scores updated more frequently than patients whose illness is less acute. Patients with a MELD score &ge;25, for example, have their scores updated weekly. Patients may have their MELD score updated more often if they experience a decline in health status. Thus, the MELD score may either increase or decrease while patients await transplantation.",
"   </p>",
"   <p>",
"    An individual patient's priority for liver transplantation depends upon the patient's MELD score, the patient's blood type, the number of other patients listed for transplant in the local area, the severity of illness of those other patients as determined by their MELD scores, and the number of deceased donor livers available in the local area. Among patients waiting in the same locale with identical blood type and MELD score, time spent on the waiting list at that score is used to break ties. If a patient experiences an increase in the MELD score (worsening of liver disease severity), the waiting time clock is set to zero and restarted at the higher score. However, according to current UNOS policy, if a patient experiences a decline in the MELD score (decreased liver disease severity), the time accumulated at the higher MELD score is maintained and added to however much time is accumulated at the lower score.",
"   </p>",
"   <p>",
"    Under the current deceased donor liver allocation system, patients with acute liver failure (UNOS status 1) are exempt from the MELD-based prioritization process outlined above. These patients are instead given highest priority over all other patients listed for liver transplantation due to the high acuity and mortality associated with their illness. However, a large study comparing wait-list mortality of patients with end-stage liver disease (n = 50,331) with the mortality of patients listed as status 1A (n = 2128) found that the 14-day wait-list mortality in patients listed with calculated MELD scores &gt;40 was significantly higher than that for status 1A patients (hazard ratio 1.96) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/33\">",
"     33",
"    </a>",
"    ]. The 14-day mortality was similar between patients listed with MELD scores from 36 to 40 and those who were status 1A. Post liver transplant survival was similar among patients transplanted with high MELD scores and those transplanted as status 1A. Although the authors argue that, on the basis of their results, patients with a calculated MELD score &gt;40 should be given priority over status 1A patients, and that patients with a MELD score of 36 to 40 should be assigned a similar priority as status 1A for transplantation, the results of this study may not be compelling enough on their own to support the recommended policy change. Specifically, the study excluded retransplant patients listed as status 1A and did not assess the impact that the suggested policy change would have on patients awaiting liver transplantation. Furthermore, the study did not adjust for practice variations among liver transplant centers, and the study also spanned a time period when both allocation and distribution policies underwent changes, which could lead to confounding. The results of this study are intriguing, but further analyses should be undertaken prior to recommending policy changes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MELD EXCEPTIONS IN LIVER TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are some special conditions, including hepatocellular carcinoma (HCC), hepatopulmonary syndrome, and select systemic metabolic diseases that are associated with chronic liver disease and result in impaired survival, but are not directly accounted for in the MELD scoring system. Thus, the calculated MELD score for such patients may not accurately reflect their increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/35\">",
"     35",
"    </a>",
"    ]. As a result, additional MELD points may be assigned to patients with these conditions in order to adjust for their increased mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Patients with hepatocellular carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HCC are assigned specific MELD scores based upon tumor burden and the associated predicted three-month survival for HCC, rather than on the traditional MELD parameters (ie, serum bilirubin, serum creatinine, and INR). Giving additional MELD points to patients with HCC initially led to a six-fold increase in the proportion of transplantation patients with HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/36\">",
"     36",
"    </a>",
"    ]. The decision to give exception status to patients with HCC is based upon two observations. First, patients with HCC who meet criteria for liver transplantation have a post-liver transplant survival that is not worse than other patients undergoing liver transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36362?source=see_link\">",
"     \"Liver transplantation for hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Second, many patients with HCC do not demonstrate the degree of hepatic synthetic dysfunction necessary to give them a competitive MELD score and thus would be given too low priority based upon calculated MELD score alone. A low calculated MELD score in a patient with HCC would translate into increased waiting time with concomitant increased risk of tumor growth during the waiting period, resulting in increased morbidity and mortality. As a result, UNOS assigned a predetermined MELD score to selected patients with HCC such that they would receive an early transplant.",
"   </p>",
"   <p>",
"    The prioritization scores for patients with HCC are based upon tumor size and number. Under the current UNOS policy for allocation of deceased donor livers for transplantation, patients with ALTSG (American Liver Tumor Study Group) stage II HCC (single HCC between 2 and 5 cm, or two to three lesions, none greater than 3 cm) who are potential liver transplant candidates are assigned an initial MELD score of 22 (",
"    <a class=\"graphic graphic_table graphicRef53242 \" href=\"UTD.htm?0/18/300\">",
"     table 3",
"    </a>",
"    ). The assignment of this relatively high MELD score reflects both an estimated three-month mortality rate of 15 percent in such patients, and the risk of the tumor progressing to a level that would render patients ineligible for transplantation within three months of listing.",
"   </p>",
"   <p>",
"    Since it is not always feasible or desirable to biopsy hepatic lesions suspected of being HCC, the following criteria are acceptable to UNOS to support the diagnosis of HCC in a patient awaiting liver transplantation: vascular blush corresponding to the area of suspicion on imaging studies, an alpha-fetoprotein (AFP) concentration &gt;200",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    an arteriogram that confirms presence of a tumor, or ablation (ie, chemoembolization, radiofrequency ablation, cryo- or chemical ablation) of the lesion. Patients with chronic liver disease who have an increasing AFP concentration of &ge;500",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    may be listed with a MELD score equivalent to an 8 percent mortality risk, even if the imaging studies do not show evidence of a tumor, but these individuals need to demonstrate an ongoing rise in the AFP in order to receive extensions of their MELD exception points. However, the predictive accuracy of this cutoff has been questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After patients have been on the waiting list for three months with an HCC MELD exception score of 22, the score is increased to reflect a corresponding increase in the estimated three-month mortality rate. For every subsequent three months spent on the waiting list, patients receive additional points corresponding to an estimated increased mortality of 10 percent. As an example, MELD scores of 30 and 32 points in an HCC patient correspond to three-month mortality rates of 35 and 45 percent, respectively.",
"   </p>",
"   <p>",
"    Under the current UNOS liver allocation policy, patients with HCC characterized by a single lesion less than 2 cm in diameter (ALTSG stage I, (",
"    <a class=\"graphic graphic_table graphicRef53242 \" href=\"UTD.htm?0/18/300\">",
"     table 3",
"    </a>",
"    )) are not assigned a higher MELD priority score. Rather, their calculated MELD score is used for listing priority. Similarly, patients with more advanced HCC, as characterized by a single tumor greater than 5 cm in diameter or more than three tumors, are not assigned higher MELD scores either. Liver transplantation centers may consider these patients with larger HCC tumor burden for transplant listing on a case-by-case basis, but the patients will be UNOS listed at their calculated MELD scores with no additional priority given for the diagnosis of HCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other MELD exceptions",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a variety of other conditions in which the calculated MELD score may not accurately represent a patient's mortality risk while awaiting liver transplantation. Therefore, patients with these select conditions who meet specific disease-related criteria may be eligible for an upgrade in MELD points, with subsequent automatic upgrades every three months, in order to more accurately represent the patient's mortality risk while awaiting liver transplantation. Aside from HCC, these MELD exception disease conditions include [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/15,38\">",
"     15,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatopulmonary syndrome, characterized by a PaO2 &lt;60 mmHg on room air",
"     </li>",
"     <li>",
"      Familial amyloid polyneuropathy",
"     </li>",
"     <li>",
"      Primary oxaluria (usually necessitating combined liver-kidney transplantation)",
"     </li>",
"     <li>",
"      Portopulmonary hypertension is defined by a mean pulmonary artery pressure &gt;25 mmHg, with a mean pulmonary artery pressure &gt;35 mmHg being associated with poor outcomes after liver transplantation. Therefore, to receive MELD exception points for portopulmonary hypertension, the mean pulmonary artery pressure must be maintained &lt;35 mmHg with treatment (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35064?source=see_link\">",
"       \"Portopulmonary hypertension\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cystic fibrosis, characterized by FEV1 &lt;40 percent",
"     </li>",
"     <li>",
"      Hilar cholangiocarcinoma, provided that the transplant center listing the patient has a written protocol detailing the work-up and management of cholangiocarcinoma patients for transplantation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a general rule, patients listed with the MELD exceptions outlined above receive a 10 percent increase in their MELD score every three months while on the waiting list, provided that they continue to meet the disease-related listing criteria.",
"   </p>",
"   <p>",
"    There are a variety of other special situations in which individual liver transplant centers may submit a petition to their regional review board for additional MELD points in order to give the patient a score that better reflects their risk of death without transplantation. The merits of these cases are decided individually.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     IMPACT OF THE MELD LIVER ALLOCATION SYSTEM FOR TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The introduction of the MELD score has, overall, improved liver allocation, although the quest for evidence-based improvements and quality assessment of the current liver allocation process is ongoing.",
"   </p>",
"   <p>",
"    A study using data from UNOS compared the outcomes of deceased donor liver transplantation in the pre-MELD era",
"    <span class=\"nowrap\">",
"     (2/27/01",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     2/26/02,",
"    </span>",
"    Era 1) to the post-MELD era",
"    <span class=\"nowrap\">",
"     (2/27/02",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     2/26/03,",
"    </span>",
"    Era 2) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/39\">",
"     39",
"    </a>",
"    ]. In the post-MELD era there was a 12 percent reduction in new patients registered onto the liver transplant waiting list, particularly patients with the lowest MELD scores because accrual of waiting time was no longer advantageous in the MELD system. As a result, the mean MELD score at the time of liver transplantation was higher in Era 2 compared with Era 1. The median waiting time on the list decreased substantially from 656 days to 416 days in Era 1 versus Era 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/40\">",
"     40",
"    </a>",
"    ]. There was a 10 percent increase in the number of deceased donor liver transplantations performed and a 3.5 percent decrease in the number of deaths on the liver transplant waiting list in Era 2. The latter finding was likely due, in part, to the increase in available donor livers, but there is a general consensus that MELD has significantly contributed to the reduction in mortality on the liver transplant waiting list [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There had been initial concern that adoption of the MELD scoring system might result in poorer transplant outcomes if livers were being allocated to patients who were \"too sick\" (those with high MELD scores). However, there was no significant change in early (three-month) patient and graft survival in Era 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/39\">",
"     39",
"    </a>",
"    ]. Because of the exception status given to patients with HCC, the number of patients with HCC who underwent liver transplantation also increased in Era 2. These data demonstrate that the new MELD allocation system has been successful in de-emphasizing waiting time as a major factor in prioritizing patients for liver transplantation. In addition, adoption of the MELD scoring system appears to have been associated with increased transplantation rates without concomitant increased mortality rates.",
"   </p>",
"   <p>",
"    In contrast to the overall benefit, there have also been some unintended consequences of the MELD allocation policy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/42\">",
"     42",
"    </a>",
"    ]. First and foremost, adoption of the MELD score, with its emphasis on renal function, has resulted in an increase in the number of combined liver-kidney transplants being performed. In addition, since the introduction of the MELD allocation policy, the liver transplant community also noted a change in the pattern of use and distribution of high-risk donor organs. Specifically, more high-risk deceased donor livers (ie, livers from older donors or donation after cardiac death [DCD] livers, etc), which in the pre-MELD era were typically used for patients in most urgent medical need of a liver transplant, were now being steered towards patients with lower MELD scores [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study evaluating this change in placement of high-risk donor livers estimated that there was a small, but statistically significant decrease in post-transplant survival in the post-MELD era among less urgent (MELD &lt;20) transplant patients who received high-risk donor livers (HR = 1.017 per year) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/44\">",
"     44",
"    </a>",
"    ]. Despite this finding, it may be unfair to entirely attribute this change in pattern of use of high-risk donors with consequent impact on post-transplant survival among the lower MELD patients to the MELD allocation system alone. Coincident with the adoption of the MELD system for liver allocation and also borne out of the severe shortage of available donor organs, there has been a national initiative to increase the use of high-risk donor livers, namely the Organ Donation Breakthrough Collaborative sponsored by the Department of Health and Human Services, which has been reasonably successful thus far [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/45\">",
"     45",
"    </a>",
"    ]. Regardless, in light of the compelling available evidence demonstrating poorer outcomes among patients with lower MELD scores (MELD &lt;20), the practice of allocating high-risk donor livers to patients with low MELD scores is changing.",
"   </p>",
"   <p>",
"    Other studies have examined the effects of the MELD allocation system on healthcare disparities, particularly as they relate to race and sex, and found that, unlike in the pre-MELD era, in the post-MELD era being black was no longer associated with either an increased risk of death on the liver transplant waiting list or increased risk of being removed from the waiting list due to being too ill [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/46\">",
"     46",
"    </a>",
"    ]. Furthermore, adoption of the MELD scoring system has resulted in race no longer being a significant factor in the likelihood of receiving a liver transplant once a patient is listed.",
"   </p>",
"   <p>",
"    Despite these encouraging findings, there is still progress to be made in the arena of access to transplantation among different racial groups that is beyond the scope of the MELD allocation system [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/47\">",
"     47",
"    </a>",
"    ]. Interestingly, analyses of the national liver transplant data have revealed that there are sex disparities in the post-MELD era. Specifically, compared with the pre-MELD era, women in the post-MELD era are more likely than men to die or become too ill for transplant, and women are also less likely to receive a liver transplant once listed, compared with men [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/46\">",
"     46",
"    </a>",
"    ]. The precise reasons for this are not completely defined, but studies have suggested that women may be at a disadvantage in the MELD system due to their generally smaller body mass and, therefore, lower creatinine levels [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. It is also likely that donor liver allocation to women is impacted by factors outside the purview of the MELD score, including matching of organ size to recipient body size [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72087837\">",
"    <span class=\"h1\">",
"     PROPOSED MODIFICATIONS OF THE MELD SCORE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refinements of the MELD score continue to be proposed (for example, MELDNa, Reweighted MELD and RefitMELD) and are driven by the liver transplant community's desire to increase the efficiency of allocation of donated livers in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72087828\">",
"    <span class=\"h2\">",
"     Serum sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia is a common problem in patients with advanced cirrhosis, and the severity of the hyponatremia is a marker of the severity of the cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17608?source=see_link&amp;anchor=H7#H7\">",
"     \"Hyponatremia in patients with cirrhosis\", section on 'Predictor of adverse prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple studies have shown that the addition of serum sodium concentration improved the predictive accuracy of the MELD score in hyponatremic patients with low MELD scores who were awaiting liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/51-58\">",
"     51-58",
"    </a>",
"    ]. This finding likely reflects the underlying hemodynamic derangements seen in end-stage liver disease, and the addition of serum sodium to the MELD model (referred to as MELDNa) is promising (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?14/39/14962?source=see_link\">",
"     calculator 5",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?11/38/11874?source=see_link\">",
"     calculator 6",
"    </a>",
"    ). Although hyponatremia is predictive of waitlist mortality independent of the MELD score, some have raised concerns that hyponatremia may also be associated with poorer outcomes in the post-liver transplant setting. However, data on this matter are conflicting, and more definitive data analyses looking at the association between hyponatremia and post-liver transplant outcomes using the most recent national data from UNOS should help clarify this issue in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72087844\">",
"    <span class=\"h2\">",
"     Reweighting of MELD components",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study using all available laboratory values for the MELD components in a more contemporary (2001 to 2006), large, national cohort of wait-listed liver transplant candidates in the United States described an updated MELD formula in which the coefficients for each of the MELD components were significantly different from the coefficients in the original MELD model [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/61\">",
"     61",
"    </a>",
"    ]. Specifically, the updated MELD formula would assign a lower weight to the serum creatinine and INR and a higher weight to serum bilirubin. The updated model performed better than the existing MELD score in predicting wait list mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72087853\">",
"    <span class=\"h2\">",
"     Refitting of MELD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most recent optimization of the MELD prognostic model system was conducted using data from the Organ Procurement and Transplantation Network on newly registered adult patients on the liver transplant waiting list in the United States from 2005 to 2008. The investigators developed and independently validated new models (the RefitMELD and RefitMELDNa models) that updated the coefficients for the MELD components and implemented new upper and lower bounds for creatinine (0.8 to 3.0",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    respectively) and for INR (1.0 and 3.0, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/62\">",
"     62",
"    </a>",
"    ]. The new models were generated with and without serum sodium in the model (RefitMELDNa and RefitMELD, respectively). The Refit models (both RefitMELD and RefitMELDNa) performed better than the existing MELD score, MELDNa, and the reweighted MELD score (see above) in predicting mortality on the liver transplant waiting list.",
"   </p>",
"   <p>",
"    These proposed refinements of the current MELD scoring system are further promising steps towards evidence-based improvements in the liver allocation process. These models will require further vetting and assessment of the impact upon wait list mortality and transplant outcomes before being considered for formal adoption on a national level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     APPLICATIONS OF MELD OUTSIDE OF LIVER TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MELD scoring system has prognostic value in a variety of clinical settings and populations of patients with liver disease extending beyond the liver transplant setting [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Transjugular intrahepatic portosystemic shunts (TIPS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MELD scoring system was initially developed as a prognostic model for patients undergoing elective TIPS, a setting in which it performed better than the CTP score in predicting three-month mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35465?source=see_link\">",
"     \"Treatment of diuretic-resistant ascites in patients with cirrhosis\"",
"    </a>",
"    .) Thus, MELD can identify a subgroup of high-risk patients with cirrhosis who, due to high post-procedure mortality, would not be suitable candidates for TIPS unless they are expected to undergo early liver transplantation. As a result, unless TIPS is indicated for emergency purposes, patients with high MELD scores who are near the top of the list for liver transplantation should generally not receive TIPS. TIPS would be best used in patients who have MELD scores associated with liver transplant list waiting times of greater than three months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/63\">",
"     63",
"    </a>",
"    ]. Consistent with these recommendations are the results of a study of 119 patients undergoing elective TIPS procedure demonstrating an increased 30-day mortality rate post-TIPS in patients with MELD score &gt;24 compared with patients with MELD &le;24 (60 versus 5-25 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Use of MELD for selecting patients for TIPS'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Alcoholic hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Discriminant Function (DF) has traditionally been used to predict survival in patients with alcoholic hepatitis (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?15/29/15825?source=see_link\">",
"     calculator 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/5\">",
"     5",
"    </a>",
"    ]. However, the DF may be somewhat limited in its applicability as it relies primarily upon measurement of the prothrombin time, which may be subject to variability among different medical laboratories. Several studies have evaluated the MELD score as a prognostic index in alcoholic hepatitis, and a simple online tool is now available, in which the MELD score has been calibrated to predict 90-day mortality among patients with alcoholic hepatitis (",
"    <a class=\"external\" href=\"file://www.mayoclinic.org/meld/mayomodel7.html\">",
"     www.mayoclinic.org/meld/mayomodel7.html",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22104?source=see_link\">",
"     \"Prognosis and management of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hepatorenal syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study of 105 consecutive patients with hepatorenal syndrome suggested that the MELD score may be a useful predictor of survival [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/64\">",
"     64",
"    </a>",
"    ]. Among patients with type 2 hepatorenal syndrome, a MELD score of &ge;20 was associated with significantly shorter transplant-free survival compared with those with lower values (median survival of 3 versus 11 months, respectively). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=see_link\">",
"     \"Hepatorenal syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cirrhosis with sepsis unrelated to spontaneous bacterial peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MELD score was the only prognostic marker useful for predicting mortality in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/65\">",
"     65",
"    </a>",
"    ]. Three-month survival was greater than 90 percent in patients with MELD &lt;20 compared with approximately 60 percent in those with MELD &ge;20. Patients who developed renal failure associated with sepsis had worse overall mortality even if the renal failure was reversible. Interestingly, the MELD score was a more accurate predictor of survival than the development of renal failure alone, which may be explained, in part, by the fact that the MELD score reflects prognosis related to both renal and liver failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     UNOS status 1 (acute liver failure)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although MELD is now the scoring system used by UNOS for prioritizing organ allocation in patients with chronic liver disease awaiting transplantation, the allocation process for patients with acute liver failure, designated as UNOS status 1, remains unchanged and currently is not based on the MELD score. In UNOS status 1 patients, deceased donor livers are allocated according to the patient's blood type, waiting time on the liver transplant list and geographic location of the patient. Patients categorized as status 1 are severely ill with a very high short-term mortality. They may be divided into two subsets: (1) fulminant hepatic failure (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and non-acetaminophen induced), and (2) early graft failure in the immediate post-transplant setting, including graft primary non-function and hepatic artery thrombosis, requiring urgent listing for retransplantation.",
"   </p>",
"   <p>",
"    Although MELD is not currently used in clinical practice for UNOS status 1 patients, the accuracy of MELD in this patient population has been evaluated. In a study that included 720 adult status 1 transplant candidates, patients with fulminant hepatic failure (non-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    induced) had the poorest overall survival on the liver transplant waiting list. Increasing MELD score was highly correlated with decreased survival in this group [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/66\">",
"     66",
"    </a>",
"    ]. However, the mortality of patients with graft primary non-function and hepatic artery thrombosis were less tightly associated with the MELD score.",
"   </p>",
"   <p>",
"    The MELD score has also been specifically assessed for its prognostic value in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    -induced hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/67\">",
"     67",
"    </a>",
"    ]. In one study, a higher MELD score was predictive of the development of fulminant hepatic failure, but once FHF developed, the MELD score was not a more accurate predictor of survival than either the King's College Criteria or the INR alone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, in a study of patients with fulminant hepatic failure due to the hepatitis A virus, MELD was only moderately accurate in predicting mortality risk in these patients (c-statistic 0.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/68\">",
"     68",
"    </a>",
"    ]. Thus, although the results of these studies suggest that MELD may have some prognostic value in fulminant hepatic failure, there are likely other parameters that are important mortality predictors in this unique patient population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=see_link\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Assessment of surgical mortality risk in liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cirrhosis are at increased risk of perioperative morbidity and mortality and the CTP score has been traditionally used to risk stratify these patients prior to surgical intervention. More recently, the MELD score has been evaluated with respect to its ability to predict perioperative mortality in patients with cirrhosis undergoing various surgical procedures. An online tool is available for determining the risk of postoperative mortality for several types of major surgery, including gastrointestinal, orthopedic, and cardiac surgery (",
"    <a class=\"external\" href=\"file://www.mayoclinic.org/meld/mayomodel9.html\">",
"     www.mayoclinic.org/meld/mayomodel9.html",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12858?source=see_link\">",
"     \"Assessing surgical risk in patients with liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168093240\">",
"    <span class=\"h2\">",
"     Assessment of mortality in trauma patients with cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cirrhosis is a well-known risk factor for increased morbidity and mortality in the setting of trauma. The association between the MELD score and outcomes among patients with chronic liver disease has been investigated in a retrospective study of 285 trauma patients with presumed cirrhosis who were evaluated at a single level-1 trauma center from 2003 to 2009. [",
"    <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/69\">",
"     69",
"    </a>",
"    ]. The investigators found that the injury severity score (ISS) and the MELD score were significant predictors of increased mortality in the setting of trauma, with the ISS explaining 48 percent of the variation in mortality and the MELD score contributing an additional 7 percent to the variation. With respect to the MELD score, trauma patients who died had a slightly higher MELD score compared with those who survived (14 versus 11, p&lt;0.001), and for each one-point increase in MELD score, the odds for mortality increased by 18 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Acute variceal hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have investigated the prognostic value of MELD in predicting mortality among patients presenting with acute variceal hemorrhage.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One found that both MELD and CTP score had similar accuracy for the prediction of mortality in this clinical setting [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another demonstrated that the MELD score and the presence of HCC were better predictors of mortality than the CTP score in patients with acute variceal bleeding, with a MELD score &ge;15 being associated with a worse prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third report confirmed the improved prognostic accuracy of MELD over the CTP score in patients with acute variceal hemorrhage and further demonstrated that patients with MELD &ge;18 who require four or more units of blood transfusion are at substantially increased risk of death in the setting of acute variceal hemorrhage compared with patients with lower MELD and lower transfusion requirement [",
"      <a class=\"abstract\" href=\"UTD.htm?15/25/15770/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;MELD is a prospectively developed and validated chronic liver disease severity scoring system that uses a patient's laboratory values for serum bilirubin, serum creatinine, and the INR to predict survival (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?21/23/21874?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). The MELD score, as currently used by UNOS in prioritizing allocation of organs for liver transplantation, is calculated according to the following formula:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MELD = 3.8[Ln serum bilirubin",
"      <span class=\"nowrap\">",
"       (mg/dL)]",
"      </span>",
"      + 11.2[Ln INR] + 9.6[Ln serum creatinine",
"      <span class=\"nowrap\">",
"       (mg/dL)]",
"      </span>",
"      + 6.4.",
"     </li>",
"     <li>",
"      Several MELD calculators that have been designed for use in specific clinical scenarios are readily available:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The UNOS MELD score, which is currently used for allocation of donor livers for transplantation in the United States: Laboratory values of INR, total bilirubin and serum creatinine that are &lt;1.0 are set to 1.0. In addition, serum creatinine levels &gt;4.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      are capped at 4.0",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      and patients on dialysis receive an assigned serum creatinine value of 4.0",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"      Thus, for the purposes of organ allocation, UNOS MELD scores can range from 6 to 40 points (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?21/23/21874?source=see_link\">",
"       calculator 1",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?18/2/18466?source=see_link\">",
"       calculator 2",
"      </a>",
"      ) (",
"      <a class=\"external\" href=\"file://www.mayoclinic.org/meld/mayomodel6.html\">",
"       www.mayoclinic.org/meld/mayomodel6.html",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The original published MELD score has neither upper nor lower limits for laboratory values. Thus, MELD scores using the original formula can range from negative values to positive infinity. This version of the MELD score is not used for donor liver allocation. (",
"      <a class=\"external\" href=\"file://www.mayoclinic.org/meld/mayomodel5.html\">",
"       www.mayoclinic.org/meld/mayomodel5.html",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A MELD score calculator that has been calibrated to predict 90-day mortality in patients with alcoholic hepatitis (",
"      <a class=\"external\" href=\"file://www.mayoclinic.org/meld/mayomodel7.html\">",
"       www.mayoclinic.org/meld/mayomodel7.html",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A MELD score calculator for predicting postoperative mortality risk in patients with cirrhosis. This calculator is based upon the first published MELD score, thus the etiology of liver disease is required for the calculation (",
"      <a class=\"external\" href=\"file://www.mayoclinic.org/meld/mayomodel9.html\">",
"       www.mayoclinic.org/meld/mayomodel9.html",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A MELD-Na calculator, which incorporates serum sodium into the model (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?14/39/14962?source=see_link\">",
"       calculator 5",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?11/38/11874?source=see_link\">",
"       calculator 6",
"      </a>",
"      ) (",
"      <a class=\"external\" href=\"file://www.mayoclinic.org/meld/mayomodel8.html\">",
"       www.mayoclinic.org/meld/mayomodel8.html",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The MELD score also has prognostic value in several clinical settings outside of liver transplantation, including predicting mortality associated with: alcoholic hepatitis, hepatorenal syndrome, fulminant hepatic failure, sepsis in cirrhosis, acute variceal hemorrhage, surgical procedures in chronic liver disease patients, and the transjugular intrahepatic portosystemic shunt (TIPS) procedure.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     www.openclinical.org/aisp_apache.html (Accessed on March 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/2\">",
"      Dickson ER, Grambsch PM, Fleming TR, et al. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/3\">",
"      Grambsch PM, Dickson ER, Kaplan M, et al. Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability. Hepatology 1989; 10:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/4\">",
"      Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000; 75:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/5\">",
"      Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75:193.",
"     </a>",
"    </li>",
"    <li>",
"     Child III, CG, Turcotte, JG. Surgery and portal hypertension. In: The Liver and Portal Hypertension, Child III CG (Ed), Saunders, Philadelphia 1964. p.50.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/7\">",
"      Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/8\">",
"      Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/9\">",
"      Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/10\">",
"      D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/11\">",
"      Freeman RB Jr, Wiesner RH, Harper A, et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 2002; 8:851.",
"     </a>",
"    </li>",
"    <li>",
"     file://optn.transplant.hrsa.gov/resources/professionalResources (Accessed on March 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/13\">",
"      Wiesner RH, McDiarmid SV, Kamath PS, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001; 7:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/14\">",
"      Christensen E, Schlichting P, Fauerholdt L, et al. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology 1984; 4:430.",
"     </a>",
"    </li>",
"    <li>",
"     file://optn.transplant.hrsa.gov/SharedContentDocuments/ (Accessed on March 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/16\">",
"      Trotter JF, Brimhall B, Arjal R, Phillips C. Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl 2004; 10:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/17\">",
"      Tripodi A, Chantarangkul V, Primignani M, et al. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 2007; 46:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/18\">",
"      Bellest L, Eschw&egrave;ge V, Poupon R, et al. A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology. Hepatology 2007; 46:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/19\">",
"      Cholongitas E, Marelli L, Kerry A, et al. Different methods of creatinine measurement significantly affect MELD scores. Liver Transpl 2007; 13:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/20\">",
"      Miller WG, Myers GL, Ashwood ER, et al. Creatinine measurement: state of the art in accuracy and interlaboratory harmonization. Arch Pathol Lab Med 2005; 129:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/21\">",
"      Said A, Williams J, Holden J, et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004; 40:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/22\">",
"      Cholongitas E, Marelli L, Shusang V, et al. A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transpl 2006; 12:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/23\">",
"      Montgomery A, Ferral H, Vasan R, Postoak DW. MELD score as a predictor of early death in patients undergoing elective transjugular intrahepatic portosystemic shunt (TIPS) procedures. Cardiovasc Intervent Radiol 2005; 28:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/24\">",
"      Ferral H, Vasan R, Speeg KV, et al. Evaluation of a model to predict poor survival in patients undergoing elective TIPS procedures. J Vasc Interv Radiol 2002; 13:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/25\">",
"      Ferral H, Gamboa P, Postoak DW, et al. Survival after elective transjugular intrahepatic portosystemic shunt creation: prediction with model for end-stage liver disease score. Radiology 2004; 231:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/26\">",
"      Freeman RB Jr, Edwards EB. Liver transplant waiting time does not correlate with waiting list mortality: implications for liver allocation policy. Liver Transpl 2000; 6:543.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine. Analysis of waiting times. In: Committee on Organ Transplantation. Assessing current policies and the potential impact of the DHHS final rule, National Academy Press, Washington DC 1999. p.57.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/28\">",
"      Organ Procurement and Transplantation Network--HRSA. Final rule with comment period. Fed Regist 1998; 63:16296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/29\">",
"      Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/30\">",
"      Ravaioli M, Grazi GL, Ballardini G, et al. Liver transplantation with the Meld system: a prospective study from a single European center. Am J Transplant 2006; 6:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/31\">",
"      Gleisner AL, Mu&ntilde;oz A, Brandao A, et al. Survival benefit of liver transplantation and the effect of underlying liver disease. Surgery 2010; 147:392.",
"     </a>",
"    </li>",
"    <li>",
"     www.unos.org (Accessed on June 12, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/33\">",
"      Sharma P, Schaubel DE, Gong Q, et al. End-stage liver disease candidates at the highest model for end-stage liver disease scores have higher wait-list mortality than status-1A candidates. Hepatology 2012; 55:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/34\">",
"      Freeman RB, Wiesner R. Should we change the priority for liver allocation for patients with the highest MELD score? Hepatology 2012; 55:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/35\">",
"      Biggins SW, Bambha K. MELD-based liver allocation: who is underserved? Semin Liver Dis 2006; 26:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/36\">",
"      Ioannou GN, Perkins JD, Carithers RL Jr. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 2008; 134:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/37\">",
"      Kemmer N, Neff G, Kaiser T, et al. An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma. Liver Transpl 2006; 12:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/38\">",
"      Freeman RB Jr, Gish RG, Harper A, et al. Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl 2006; 12:S128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/39\">",
"      Freeman RB, Wiesner RH, Edwards E, et al. Results of the first year of the new liver allocation plan. Liver Transpl 2004; 10:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/40\">",
"      Kamath PS, Kim WR, Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology 2007; 45:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/41\">",
"      Brown RS Jr, Lake JR. The survival impact of liver transplantation in the MELD era, and the future for organ allocation and distribution. Am J Transplant 2005; 5:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/42\">",
"      Freeman RB Jr. Model for end-stage liver disease (MELD) for liver allocation: a 5-year score card. Hepatology 2008; 47:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/43\">",
"      Schaubel DE, Sima CS, Goodrich NP, et al. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008; 8:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/44\">",
"      Volk ML, Lok AS, Pelletier SJ, et al. Impact of the model for end-stage liver disease allocation policy on the use of high-risk organs for liver transplantation. Gastroenterology 2008; 135:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/45\">",
"      Shafer TJ, Wagner D, Chessare J, et al. US organ donation breakthrough collaborative increases organ donation. Crit Care Nurs Q 2008; 31:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/46\">",
"      Moylan CA, Brady CW, Johnson JL, et al. Disparities in liver transplantation before and after introduction of the MELD score. JAMA 2008; 300:2371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/47\">",
"      Thuluvath PJ, Guidinger MK, Fung JJ, et al. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010; 10:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/48\">",
"      Cholongitas E, Marelli L, Kerry A, et al. Female liver transplant recipients with the same GFR as male recipients have lower MELD scores--a systematic bias. Am J Transplant 2007; 7:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/49\">",
"      Bambha KM, Biggins SW. Inequities of the Model for End-Stage Liver Disease: an examination of current components and future additions. Curr Opin Organ Transplant 2008; 13:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/50\">",
"      Lai JC, Terrault NA, Vittinghoff E, Biggins SW. Height contributes to the gender difference in wait-list mortality under the MELD-based liver allocation system. Am J Transplant 2010; 10:2658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/51\">",
"      Heuman DM, Abou-Assi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004; 40:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/52\">",
"      Luca A, Angermayr B, Bertolini G, et al. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl 2007; 13:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/53\">",
"      Londo&ntilde;o MC, C&aacute;rdenas A, Guevara M, et al. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut 2007; 56:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/54\">",
"      Biggins SW, Kim WR, Terrault NA, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006; 130:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/55\">",
"      Ruf AE, Kremers WK, Chavez LL, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005; 11:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/56\">",
"      Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008; 359:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/57\">",
"      Guy J, Somsouk M, Shiboski S, et al. New model for end stage liver disease improves prognostic capability after transjugular intrahepatic portosystemic shunt. Clin Gastroenterol Hepatol 2009; 7:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/58\">",
"      Biselli M, Gitto S, Gramenzi A, et al. Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: Which is the winner? Liver Transpl 2010; 16:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/59\">",
"      Londo&ntilde;o MC, Guevara M, Rimola A, et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology 2006; 130:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/60\">",
"      Yun BC, Kim WR, Benson JT, et al. Impact of pretransplant hyponatremia on outcome following liver transplantation. Hepatology 2009; 49:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/61\">",
"      Sharma P, Schaubel DE, Sima CS, et al. Re-weighting the model for end-stage liver disease score components. Gastroenterology 2008; 135:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/62\">",
"      Leise MD, Kim WR, Kremers WK, et al. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation. Gastroenterology 2011; 140:1952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/63\">",
"      Rosado B, Kamath PS. Transjugular intrahepatic portosystemic shunts: an update. Liver Transpl 2003; 9:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/64\">",
"      Alessandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005; 41:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/65\">",
"      Terra C, Guevara M, Torre A, et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 2005; 129:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/66\">",
"      Kremers WK, van IJperen M, Kim WR, et al. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. Hepatology 2004; 39:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/67\">",
"      Schmidt LE, Larsen FS. MELD score as a predictor of liver failure and death in patients with acetaminophen-induced liver injury. Hepatology 2007; 45:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/68\">",
"      Taylor RM, Davern T, Munoz S, et al. Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes. Hepatology 2006; 44:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/69\">",
"      Inaba K, Barmparas G, Resnick S, et al. The Model for End-Stage Liver Disease score: an independent prognostic factor of mortality in injured cirrhotic patients. Arch Surg 2011; 146:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/70\">",
"      Chalasani N, Kahi C, Francois F, et al. Model for end-stage liver disease (MELD) for predicting mortality in patients with acute variceal bleeding. Hepatology 2002; 35:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/71\">",
"      Amitrano L, Guardascione MA, Bennato R, et al. MELD score and hepatocellular carcinoma identify patients at different risk of short-term mortality among cirrhotics bleeding from esophageal varices. J Hepatol 2005; 42:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/25/15770/abstract/72\">",
"      Bambha K, Kim WR, Pedersen R, et al. Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis. Gut 2008; 57:814.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1241 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-37992F4EF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_25_15770=[""].join("\n");
var outline_f15_25_15770=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MELD OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEVELOPMENT OF MELD IN PATIENTS WITH CHRONIC LIVER DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      COMPARISON OF MELD AND CHILD-PUGH SCORING SYSTEMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      USE OF MELD FOR SELECTING PATIENTS FOR TIPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ADOPTION OF MELD FOR DECEASED DONOR LIVER ALLOCATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MELD EXCEPTIONS IN LIVER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Patients with hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other MELD exceptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      IMPACT OF THE MELD LIVER ALLOCATION SYSTEM FOR TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H72087837\">",
"      PROPOSED MODIFICATIONS OF THE MELD SCORE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72087828\">",
"      Serum sodium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72087844\">",
"      Reweighting of MELD components",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72087853\">",
"      Refitting of MELD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      APPLICATIONS OF MELD OUTSIDE OF LIVER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Transjugular intrahepatic portosystemic shunts (TIPS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Alcoholic hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cirrhosis with sepsis unrelated to spontaneous bacterial peritonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      UNOS status 1 (acute liver failure)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Assessment of surgical mortality risk in liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H168093240\">",
"      Assessment of mortality in trauma patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Acute variceal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/1241\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1241|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/63/14333\" title=\"figure 1\">",
"      MELD three month survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1241|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/0/13323\" title=\"table 1\">",
"      Child Turcotte classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/21/8540\" title=\"table 2\">",
"      Child Pugh classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/18/300\" title=\"table 3\">",
"      Liver tumor study group HCC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?21/23/21874?source=related_link\" title=\"calculator 1\">",
"      Calculator: MELD score for end-stage liver disease (not appropriate for patients under the age of 12)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?18/2/18466?source=related_link\" title=\"calculator 2\">",
"      Calculator: MELD score for end-stage liver disease (not appropriate for patients under the age of 12) (SI units)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?27/26/28065?source=related_link\" title=\"calculator 3\">",
"      Calculator: Child Pugh classification for severity of liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?28/28/29121?source=related_link\" title=\"calculator 4\">",
"      Calculator: Child Pugh classification for severity of liver disease (SI units)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?14/39/14962?source=related_link\" title=\"calculator 5\">",
"      Calculator: MELDNa score for end-stage liver disease (not appropriate for patients under the age of 12)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?11/38/11874?source=related_link\" title=\"calculator 6\">",
"      Calculator: MELDNa score for end-stage liver disease (not appropriate for patients under the age of 12) (SI units)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?15/29/15825?source=related_link\" title=\"calculator 7\">",
"      Calculator: Hepatitis discriminant function for corticosteroid therapy in alcoholic hepatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=related_link\">",
"      Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12858?source=related_link\">",
"      Assessing surgical risk in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34153?source=related_link\">",
"      Clinical manifestations and diagnosis of hepatic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=related_link\">",
"      Hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17608?source=related_link\">",
"      Hyponatremia in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36362?source=related_link\">",
"      Liver transplantation for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35064?source=related_link\">",
"      Portopulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22104?source=related_link\">",
"      Prognosis and management of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24022?source=related_link\">",
"      Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35465?source=related_link\">",
"      Treatment of diuretic-resistant ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_25_15771="Tumor vertebral pain synd";
var content_f15_25_15771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tumor-related vertebral pain syndromes in cancer patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Characteristics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Atlantoaxial destruction and odontoid fracture",
"       </td>",
"       <td>",
"        Nuchal or occipital pain that often radiates over the posterior aspect of the skull",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients usually present with insidious neurological deficits in one or more extremities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C7-T1 syndrome",
"       </td>",
"       <td>",
"        Pain in the interscapular region caused by tumor invasion of a C7 or T1 vertebra",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T12-L1 syndrome",
"       </td>",
"       <td>",
"        Referred pain at the ipsilateral crest or sacroiliac joint caused by tumor invasion of a T12 or L1 vertebra",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Sacral syndrome",
"       </td>",
"       <td>",
"        Pain radiating to buttocks, perineum, or posterior thighs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intense pain with hip adduction and internal rotation due to stretching of pyriformis muscle",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_25_15771=[""].join("\n");
var outline_f15_25_15771=null;
var title_f15_25_15772="Sedative herbal ingredients";
var content_f15_25_15772=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=48\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=48\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sedative herbal ingredients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calamus",
"       </td>",
"       <td>",
"        Potentiation barbituate sleeping time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Celery",
"       </td>",
"       <td>",
"        In vivo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chamomile, German",
"       </td>",
"       <td>",
"        Human",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Couchgrass",
"       </td>",
"       <td>",
"        In vivo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elecampane",
"       </td>",
"       <td>",
"        In vivo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ginseng",
"       </td>",
"       <td>",
"        CNS depressant and stimulant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Goldenseal",
"       </td>",
"       <td>",
"        In vivo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hops",
"       </td>",
"       <td>",
"        In vivo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrocotyle",
"       </td>",
"       <td>",
"        In vivo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jamaica Dogwood",
"       </td>",
"       <td>",
"        In vivo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nettle",
"       </td>",
"       <td>",
"        CNS depression, in vivo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Passionflower",
"       </td>",
"       <td>",
"        In vivo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sage",
"       </td>",
"       <td>",
"        In vivo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scullcap",
"       </td>",
"       <td>",
"        Reputed action",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shepherd's Purse",
"       </td>",
"       <td>",
"        Potentiation barbituate sleeping time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        St. John's Wort",
"       </td>",
"       <td>",
"        Traditional use, bioflavonoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valerian",
"       </td>",
"       <td>",
"        Human, in vivo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wild carrot",
"       </td>",
"       <td>",
"        In vivo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wild lettuce",
"       </td>",
"       <td>",
"        In vivo, related species",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals, The Pharmaceutical Press, London 1996. p.283.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_25_15772=[""].join("\n");
var outline_f15_25_15772=null;
var title_f15_25_15773="Endo biopsy recs";
var content_f15_25_15773=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The role of endomyocardial biopsy in fourteen clinical scenarios",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Scenario number",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical scenario",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class of recommendation (I, IIa, IIb, III)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Level of evidence (A,B,C)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        New onset heart failure of",
"        <strong>",
"         less than 2 weeks",
"        </strong>",
"        duration associated with a normal size or dilated left ventricle and hemodynamic compromise",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        New onset heart failure of",
"        <strong>",
"         2 weeks to 3 months",
"        </strong>",
"        duration associated",
"        <strong>",
"         with",
"        </strong>",
"        a dilated left ventricle, and new ventricular arrhythmias, second or third degree heart block, or failure to respond to usual care within 1 to 2 weeks",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Heart failure of",
"        <strong>",
"         greater than 3 months",
"        </strong>",
"        duration associated",
"        <strong>",
"         with",
"        </strong>",
"        a dilated left ventricle and new ventricular arrhythmias, second or third degree heart block, or failure to respond to usual care within 1 to 2 weeks",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        Heart failure associated with a dilated cardiomyopathy of any duration associated with suspected allergic reaction and/or eosinophilia",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        Heart failure associated with suspected anthracycline cardiomyopathy",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        Heart failure associated with unexplained restrictive cardiomyopathy",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        Suspected cardiac tumors",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        Unexplained cardiomyopathy in children",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        New onset heart failure of",
"        <strong>",
"         2 weeks to 3 months",
"        </strong>",
"        duration associated with a dilated left ventricle,",
"        <strong>",
"         without",
"        </strong>",
"        new ventricular arrhythmias, or second or third degree heart block, and that responds to usual care within 1 to 2 weeks",
"       </td>",
"       <td>",
"        IIb",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        Heart failure of",
"        <strong>",
"         greater than 3 months",
"        </strong>",
"        duration associated with a dilated left ventricle,",
"        <strong>",
"         without",
"        </strong>",
"        new ventricular arrhythmias, or second or third degree heart block, and that responds to usual care within 1 to 2 weeks",
"       </td>",
"       <td>",
"        IIb",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        Heart failure associated with unexplained hypertrophic cardiomyopathy",
"       </td>",
"       <td>",
"        IIb",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        Suspected arrhythmogenic right ventricular dysplasia/cardiomyopathy",
"       </td>",
"       <td>",
"        IIb",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        Unexplained ventricular arrhythmias",
"       </td>",
"       <td>",
"        IIb",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        Unexplained atrial fibrillation",
"       </td>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cooper, LT, Baughman, KL, Feldman, AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 2007; 116:2216. Copyright &copy;2007 Lippincott Williams and Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_25_15773=[""].join("\n");
var outline_f15_25_15773=null;
var title_f15_25_15774="C3a concentrations in pts on HD";
var content_f15_25_15774=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F61355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F61355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Graph showing plasma C3a concentrations in patients on hemodialysis with different dialyzers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 237px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Venous plasma levels of C3a antigen during hemodialysis with four different types of dialyzers. Complement activation was greatest with cuprophan, intermediate with cellulose acetate and minimal with cuprophan membranes reused for the third time or with polyacrylonitrile.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Chenoweth, DE, Artif Organs 1984; 8:281.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_25_15774=[""].join("\n");
var outline_f15_25_15774=null;
var title_f15_25_15775="PIT scores for EATL survival";
var content_f15_25_15775=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F53490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F53490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 575px\">",
"   <div class=\"ttl\">",
"    Survival of patients with enteropathy associated T-cell lymphoma according to Prognostic Index for PTCL, unspecified (PIT) score",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 555px; height: 614px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PIT: prognostic index for peripheral T-cell lymphoma; EATL: enteropathy-associated T-cell lymphoma.",
"    </div>",
"    <div class=\"reference\">",
"     This research was originally published in Blood. Delabie J, Holte H, Vose JM, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project. Blood 2011; 118:148. Copyright &copy; 2011 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_25_15775=[""].join("\n");
var outline_f15_25_15775=null;
